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Proteomic analysis of redox-dependent 
AGR2 complexes reveals a novel mucin 
quality control system in oesophageal 
adenocarcinoma 
 
Jack Christopher Peter Worfolk 
 
Abstract: Disulphide bonds covalently linking cysteine residues, intramolecularly or 
intermolecularly, are often essential in ensuring the stability of secreted and cell 
surface proteins as well as facilitating correct spatial positioning of protein active 
sites. The protein disulphide isomerase (PDI) family of proteins catalyse the 
oxidation, reduction and isomerisation of these disulphide bonds. PDI proteins are 
vital for protein quality control and most are found ubiquitously. Anterior gradient-2 
(AGR2) is an unusual tissue-restricted member of the PDI family that has gained 
considerable attention in the last 15 years because of its overexpression in a variety 
of different cancer types, including oesophageal adenocarcinoma. In this thesis it has 
been demonstrated that the OE19 late stage oesophageal adenocarcinoma cell line 
strongly expresses AGR2, and that in this cell line AGR2 can form redox-inducible, 
disulphide bond dependent complexes. It has also been shown, through the 
development and use of a novel, unbiased trapping and immunoprecipitation 
approach, that these AGR2 interacting proteins can be identified and compared. This 
approach has identified mucin isoforms that AGR2 preferentially binds as its primary 
clients and has revealed a host of ER chaperones involved in this quality control 
complex. This thesis lays the groundwork for the elucidation and definition of an 
AGR2-mucin quality control system within oesophageal adenocarcinoma and 
provides biomarkers and potential therapeutic targets for identification and 
treatment of AGR2-positive cancers.  
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1. Introduction 
1.1 The endoplasmic reticulum and chaperones 
The major defining feature of eukaryotic cells, distinguishing them from prokaryotic 
cells, is the presence of organelles - membrane bound compartments which allow 
our cells to organise themselves and provide specialised microenvironments for 
specific purposes. While the textbook examples of organelles described them as 
individual and sperate compartments each with their own microenvironment, 
research in recent years has shed light on the importance of membrane contact sites 
(MCSs) (Wu et al., 2018). MScs are sites where organelles do not fuse but tether to 
one another, allowing highly regulated interorganelle communication and facilitating 
such complex processes as lipid and ion transfer as well as organelle division. These 
recent developments have highlighted the dynamic nature of organelles and the 
importance of interorganelle communication for regulating homeostasis. The 
secretory pathway within eukaryotic cells is comprised of a series of these organelles 
that process and transport a wide variety of products to various locations, including 
secretion outside of the cell. The secretory pathway provides a sophisticated 
processing and delivery system for complex protein structures to a variety of target 
locations. Proteins processed through the secretory pathway include secreted 
proteins, membrane bound proteins, lysosomal enzymes and proteins residing with 
the secretory pathway itself. 
The endoplasmic reticulum (ER) is located at the start of the secretory pathway and 
is involved in a variety of different processes including lipid synthesis, Ca2+ handling 
as well as protein synthesis, folding, modification and transport (Baumann and Walz, 
2001). While protein folding and maturation does occur in the cytosol, it is not 
optimized to the same extent as the lumen of the ER. Upon translation into the ER 
lumen, proteins must acquire the correct folding conformation if they are to function 
properly. Proteins which are persistently incorrectly folded are not transported to 
their correct destination and are instead degraded. This process of protein quality 
control is essential as not only are misfolded proteins unlikely to function properly, 
they are prone to aggregation. Aggregated proteins are involved in a range of 
neurodegenerative diseases such as ALS, Alzheimer’s, Huntington’s, Parkinson’s and 
prion diseases (Ross and Poirier, 2004). 
Assisting in the process of protein quality control are the protein chaperones. These 
proteins reside in the ER at high concentrations and recognise misfolded proteins, 
either promoting folding to the correct conformation, or directing improperly folded 
proteins for destruction. The chaperone proteins are vital for protein quality control, 
and ensuring only native conformers are allowed to exit the ER is essential as protein 
quality control takes place within the ER, but not in the ER-Golgi intermediate 
16 
 
compartment or the Golgi complex itself (Mezzacasa and Helenius, 2002). Several 
processes involved in protein folding occur only in the ER. These include signal 
peptide cleavage, GPI-anchor attachment, N-linked glycosylation and, most 
importantly for this thesis, disulphide bond oxidation, isomerisation and reduction. 
1.2 Disulphide bonds, bridges and isomerases 
Disulphide bonds play a pivotal role in protein maturation and are often essential for 
the stability and function of final protein structures. Disulphide bond formation takes 
place within the oxidising environment of the ER when two free thiol (SH) groups 
from the side chains of cysteine residues are covalently linked, either 
intramolecularly or intermolecularly, through an oxidation reaction. This process is 
known as oxidative protein folding and is often prone to error, resulting in non-native 
disulphide bonds. When this occurs the disulphide must be reduced before the 
correct bond can be formed. Catalysing the oxidation, reduction and isomerisation 
of these disulphide bonds are the protein disulphide isomerase (PDI) family of 
proteins.  
PDI family members are defined by the presence of one or more thioredoxin-like 
domains, similar to the small 10 kDa oxidoreductase thioredoxin, and an active site 
CXXC motif (or similar) from which transient disulphide bonds are formed with their 
interaction partners. In humans, there are 21 known members of the PDI family. 
Some of these proteins are ubiquitous and essential for normal cellular function, such 
as Protein Disulphide Isomerase (PDI) (crystal structure shown in Figure 1), while 
others are tissue-restricted and adapted to catalyse the correct folding and secretion 
of specific client proteins, such as Anterior gradient-2.  
 
 
 
 
 
 
 
 
 
Figure 1: Crystal structure of Yeast Protein Disulphide Isomerase (2B5E from the 
protein databank (PDB) database). The four thioredoxin domains of PDI are displayed, 
as well as a Ba2+ barium ion shown as a circle to the right of the structure. 
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1.3 Anterior gradient-2 (AGR2) 
Anterior gradient-2 (AGR2) is an unusual member of the PDI family of proteins but 
has gained considerable attention in the last 15 years due to its derepression and 
oncogenic properties in a variety of different cancer types. The first discovery of the 
anterior gradient proteins came when studying the embryogenesis of Xenopus laevis, 
where Xenopus anterior gradient-2 (XAG-2) was found to be a secreted protein 
expressed in the cement gland, an ectoderm-derived organ aiding anteroposterior 
development (Aberger et al., 1998). Shortly after, the human homologue hAG-2 (later 
referred to as AGR2) was found to be coexpressed with the estrogen receptor in 
several breast cancer cell lines, suggesting a possible role for AGR2 in breast tumour 
biology (Thompson and Weigel, 1998). Since then overexpression of AGR2 has been 
found in a variety of other types of adenocarcinomas including prostate (Zhang et al., 
2005), oesophageal (Pohler et al., 2004), pancreatic (Ramachandran et al., 2008), 
ovarian (Park et al., 2011) and lung (Zhu et al., 2007). The exact role of AGR2 in 
tumour cell biology is slowly being elucidated, but already it has been shown to play 
key roles in cell growth, proliferation (Pohler et al., 2004), adhesion and metastasis 
(Liu et al., 2005). 
As well as its role in cancer progression, AGR2 performs a physiological role as a 
protein chaperone, and is natively expressed in tissue such as lung, prostate, bladder, 
as well as the gastro-intestinal tract (Fagerberg et al., 2014). In these tissues it has 
been shown to be required for the correct folding and secretion of mucins, the large 
gel-forming glycoproteins that give mucus its viscoelastic properties (Park et al., 
2009; Schroeder et al., 2012). Mucins contain large numbers of cysteine residues that 
form intra and interchain disulphide bonds which give mucus its structure. AGR2 is 
required for the correct synthesis of these disulphide bonds, although the exact 
mechanism by which it performs its function is unknown.  
As mentioned previously, PDI family members are classified by the presence of at 
least one thioredoxin-like domain, whether it be enzymatically active or not. Unlike 
most other PDI family members AGR2 contains only one thioredoxin-like domain 
with an unusual CXXS motif. The primary structure of AGR2 is displayed in Figure 2. 
This motif has been shown to lack the catalytic oxidase activity found in other 
members of the PDI family (Nørgaard and Winther, 2001). The absence of oxidase 
activity in this motif suggests that AGR2 is not a typical PDI and leads to the possibility 
that it relies on other interacting partners to perform its biological function. 
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Additionally, AGR2 contains a non-optimal KTEL ER localisation signal, removal or 
alteration of which will affect its localisation and function (Gupta et al., 2012). 
Normally, ER resident proteins possess a KDEL ER localisation signal at their C 
terminal which is recognised by the KDEL receptors in the cis Golgi. Proteins with this 
KDEL motif that have travelled to the cis Golgi are recognised by the KDEL receptors 
and are transported back to the ER, thus maintaining their concentrations without 
the need for fast translation rates. The presence of the non-optimal KTEL ER 
localisation signal at the C terminal of AGR2 prompts the question of where exactly 
within the cell it is localised. Multiple studies have shown that AGR2 is primarily 
localised to the ER (Gupta et al., 2012; Higa et al., 2011; Park et al., 2009; Zhao et al., 
2010), however the non-optimal KTEL motif still may allow AGR2 to travel beyond 
the ER. 
More recently a substrate binding loop has also been identified in AGR2 (Maslon et 
al., 2010). This was shown to be involved with its interaction with the nuclear DNA 
binding protein Reptin and is a possible route for AGR2 interactions to take place. 
This will be expanded upon later in section 1.5. 
1.4 The physiological role of AGR2 
As mentioned previously, one of the more significant roles of AGR2 involves its 
interaction with the mucin proteins, a major component of mucus. A study by Park 
et al., (2009) showed that Agr2-/- mice lacked intestinal mucus and had undetectable 
levels of the MUC2 protein and little to no MUC2 synthesis in the small intestine. It 
was also shown in this study that AGR2 deficient mice had increased susceptibility to 
intestinal disease, and with aging these mice often developed symptoms of colitis, 
including rectal prolapse. Knockout studies with other PDI family members such as 
ERp57 have resulted in embryonic lethality (Garbi et al., 2006). Although AGR2 
knockout in mice produces a disease prone phenotype, it does not result in 
embryonic lethality and demonstrates AGR2’s role as a highly specific PDI member 
primarily involved in mucus production. 
Figure 2: The primary structure of AGR2.  
Shaded boxes indicate identified domains and motifs involved in the function and 
regulation of AGR2. Taken from Chevet et al. 2013 doi:10.1038/onc.2012.346.  
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AGR2 has also been shown to interact with airway mucins MUC5AC and MUC5B, as 
demonstrated by Schroeder et al., (2012). Co-immunoprecipitation experiments 
showed that AGR2 interacts with immature MUC5AC in airway cells, and analysis of 
airway epithelial gene expression showed a correlation between AGR2 and MUC5AC 
expression. In this study they also demonstrated that germline Agr2-/- mice had a 
greater than 50% reduction in MUC5AC and MUC5B protein levels compared to wild 
type mice, suggesting AGR2 plays a crucial role in the processing of MUC5AC and 
MUC5B. Taken together, these studies highlight the crucial role of AGR2 in the 
synthesis of certain mucin isoforms and opens up the question of how exactly it 
mediates this role. 
Another study, this time using germline and inducible Agr2-/- mice, demonstrated the 
importance of AGR2 in both the goblet and Paneth cells of the intestinal crypts (Zhao 
et al., 2010). It was observed that in both germline and inducible Agr2-/- mice goblet 
cell lineage remains; however, they lose their normal morphology and intestinal 
mucus is decreased. In the same Agr2-/- mice they showed several abnormalities in 
Paneth cells. An enlargement of the Paneth cell compartment was observed as well 
as mislocalized Paneth cells in the upper crypt and villi. Agr2-/- mice were also found 
to be highly susceptible to experimentally induced ileitis and colitis. The phenotype 
observed in this study was compared to Crohn’s disease, and in another study genetic 
variants of the Agr2 gene that decrease its mRNA expression induce the ulcerative 
colitis phenotype (Zheng et al., 2006) suggesting AGR2 plays a key role in regulating 
inflammatory bowel disease. These knockout mice studies have shown the 
importance of AGR2 in mucus secretion and demonstrated the vital role it plays in 
regulating gastrointestinal diseases. 
1.5 Interacting partners for AGR2 
Through the use of yeast two-hybrid screens and a variety of other studies AGR2 has 
been shown to interact, directly or indirectly, with a large number of other proteins 
in the human body. The first and perhaps the most important for determining its 
direct role in humans, previously mentioned in section 1.4, was the discovery of its 
interaction with mucin 2 (MUC2) (Park et al., 2009). It was shown that MUC2, an 
integral component of intestinal mucus, requires AGR2 to fold properly and therefore 
function. In co-immunoprecipitation experiments AGR2 was shown to co-
immunoprecipitate with MUC2, an interaction that disappeared when the single 
cysteine residue in AGR2 was mutated. From this they concluded AGR2 forms mixed 
disulphide bonds with MUC2, establishing AGR2 as a highly specific PDI family 
member. 
The ability of AGR2 to interact with itself to form homodimers was first shown by Ryu 
et al., (2013) who provided evidence that this ability is facilitated by the formation of 
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an intermolecular disulphide bond, and that the dimerization is required for 
interaction with BiP. Paradoxically, shortly afterwards Patel et al., (2013) showed 
AGR2 existed in a monomer-dimer equilibrium within the ER at a K(d) of 8.83 µM, 
but provided data suggesting that the only cysteine residue within AGR2 was not 
necessary for dimer formation. They instead provided evidence that the dimer 
interaction was provided by salt bridges connecting the antiparallel arrangement of 
the alpha1 helices of the two molecules. If the dimer interaction does not require the 
CXXS motif cysteine residue it opens the possibility that the dimer conformation is 
used in interactions involving intermolecular disulphide bonds, such as MUC2 folding. 
Using yeast two-hybrid screening in breast tumour tissues it was found that both 
metastasis-associated GPI-anchored C4.4a protein and extracellular alpha-
dystroglycan (DAG-1) acted as binding partners for AGR2 (Fletcher et al., 2003). With 
both proteins involved in interactions with the extracellular matrix this has been 
suggested as a possible route for AGR2 to affect tumour cell metastasis, migration 
and invasion. Another protein found to interact with AGR2 through the use of yeast 
two-hybrid screening was the nuclear DNA binding protein Reptin (Maslon et al., 
2010). With the use of site directed mutagenesis, a small substrate binding loop in 
AGR2 was determined to be the docking site for its interaction with Reptin and two 
ATP binding motifs on Reptin were found to be involved in regulation of the 
AGR2:Reptin complex. As Reptin can act as a regulator of tumour suppressor genes, 
this interaction suggests that a possible route for AGR2 as a prometastatic factor 
could be through gene regulation.  
Almost all cancers, when they reach a certain stage, have either a mutated 
dysfunctional p53 gene or p53 activity is suppressed in one way or another. It is 
therefore not surprising that in 2003 AGR2 was shown to suppress p53 activity 
(Pohler et al., 2004). Cells transfected with AGR2 showed distinctly less p53 
phosphorylation at both Ser15 and Ser392, after UV-induced DNA damage, 
compared to cells without AGR2. This was determined later to be mediated through 
AGR2’s upregulation of DUSP10, a phosphatase that inactivates p53 along with 
another regulator of apoptosis, p38 MAPK (Hrstka et al., 2016). AGR2’s ability to 
suppress p53 activity gives strong evidence towards its role as a regulator of tumour 
growth. 
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A wide variety interacting partners for AGR2 have been discovered and even more 
processes and pathways have been shown to be regulated by AGR2 (Figure 3) 
indicating the importance of AGR2 in the environments in which it is expressed.  
1.6 Barrett’s oesophagus and oesophageal adenocarcinoma 
The development of oesophageal adenocarcinomas is often preceded by a condition 
called Barrett’s oesophagus. Repeated gastro-oesophageal reflux and chronic 
exposure of the normal squamous oesophageal epithelium to gastric and duodenal 
contents can result in an adaptive response in some individuals. A metaplasia and 
dysplasia of the oesophageal epithelium can occur, activating glycoprotein synthesis 
machinery to produce mucus as a defence mechanism against the change in 
environment. This transition to a mucus secreting columnar epithelium results in a 
condition known as Barrett’s oesophagus, or Barrett’s epithelium. Although not 
cancerous, Barrett’s oesophagus is considered a pre-malignant condition as there is 
a high chance (estimated between 0.5-2% per year) patients with Barrett’s will 
develop oesophageal adenocarcinoma (Nancarrow et al., 2011). Patients with 
Barrett’s oesophagus are estimated to have a 30-fold higher chance of developing 
oesophageal adenocarcinoma when compared to the general population 
(Solaymani-Dodaran et al., 2004). 
The transition to Barrett’s oesophagus is accompanied by a whole host of changes to 
gene expression, including the elevated expression of mucins such as MUC2 and 
MUC5AC (DiMaio et al., 2012). Along with mucins, AGR2 has been shown to be 
universally upregulated in Barrett’s oesophagus (Pizzi et al., 2012; Pohler et al., 
Figure 3: Major interacting partners for AGR2. 
A diagram summarizing the major known interacting partners for AGR2 described in 
sections 1.4 and 1.5. Straight lines indicate binding interactions (whether direct or 
indirect), arrows indicate upregulation of activity and flat ended lines indicate inhibition 
of activity. 
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2004). Unlike other cancers that overexpress and secrete AGR2, the overexpression 
of AGR2 in Barrett’s oesophagus is assumed to be involved in the glycoprotein 
synthesis machinery. This aberrant expression of AGR2 has been proposed as a 
biomarker for Barrett’s oesophagus (DiMaio et al., 2012). 
1.7 Thesis Aims 
Previous work by Simpson and Benham (unpublished data) showed that AGR2 is 
strongly expressed in the OE19 late stage oesophageal adenocarcinoma 
immortalised cell line, used as a model for Barrett’s oesophagus. Their work 
suggested AGR2 complex formation was affected by treatment with the reductant 
dithiothreitol (DTT), visible through non-reducing western blotting. The aims of this 
thesis are to determine whether these changes observed were the result of an 
altered redox state, or due to the ER stress induced by DTT. Additionally, through the 
use of immunoprecipitation and mass spectrometry, the interactions AGR2 makes to 
form these complexes and the interacting partners involved will be investigated. 
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2. Materials and methods 
2.1 Chemicals 
Chemicals were from Sigma-Aldrich unless otherwise stated. 
2.2 Antibodies 
Rabbit polyclonal PDI antibody from our laboratory has previously been described 
(Benham 2000). Rabbit polyclonal calnexin antibody was a gift from Prof. Masuru 
Okabe, Osaka University. Rabbit monoclonal anti-AGR2 (D9V2F) XP (13062), rabbit 
polyclonal anti-Phospho-eIF2α (Ser51) (9721), rabbit polyclonal anti-BiP (3183), 
rabbit polyclonal anti-ERp57 (G117), rabbit monoclonal anti-ERp44 (D17A6) XP 
(3798) and mouse monoclonal anti-Myc-Tag (9B11) were purchased from Cell 
Signaling Technologies. Rabbit monoclonal anti-AGR2 (EPR3278/ab76473), mouse 
monoclonal anti-β-actin (ab8224), rabbit monoclonal anti-MUC5AC 
(EPR16904/ab198294), rabbit polyclonal anti-ERp29 (ab11420), mouse monoclonal 
anti-PrdxIV (7A1) (ab16943) and rabbit monoclonal anti-GAL4 
(EPR12710(B)/ab175185) were purchased from abcam. Mouse monoclonal anti-PDI 
RL-90 (MA3-019) was purchased from ThermoFisher Scientific. Mouse monoclonal 
anti-PAUF/ZG16B (817310) was purchased from Nous Biologicals. Rabbit polyclonal 
anti-PDI was produced in our laboratory and has previously been described (Benham 
2000). Secondary antibodies used in western blotting were swine anti-rabbit HRP 
(SARPO P0217) and goat anti-mouse HRP (GAMPO P0447) conjugates from DAKO. 
Donkey anti-rabbit Alexa Fluor 488 (A21206) and donkey anti-rabbit Alexa Fluor 594 
(A21207) from ThermoFisher Scientific were used in immunofluorescence. 
Antibody dilutions for western blotting were as follows: anti-AGR2 (D9V2F), 1:1000; 
anti-BiP, 1:1000; anti-β-actin, 1:10,000; anti-CNX, 1:2000; anti-ERp29, 1:1000; anti-
ERp44, 1:1000; anti-ERp57, 1:1000; anti-GAL4, 1:1000; anti-MUC5AC, 1:10,000; anti-
Myc, 1:1000; anti-PAUF/ZG16B, 1 µg/ml; anti-PDI pAb, 1:1000; anti-PDI (RL-90), 
1:1000; anti-PrdxIV, 1:2000; anti-P-eIF2α, 1:500. Secondary antibody dilutions for 
western blotting were as follows: swine anti-rabbit HRP, 1:3000; goat anti-mouse 
HRP, 1:3000. Antibody dilutions for immunofluorescence were as follows: anti-PDI 
pAb, 1:200; anti-AGR2 (D9V2F), 1:200; anti-PrdxIV, 1:200. Secondary antibody 
dilutions for immunofluorescence were as follows: donkey anti-rabbit Alexa Fluor 
488, 1:1000; donkey anti-rabbit Alexa Fluor 594, 1:1000. Antibody dilutions for 
immunoprecipitation were as follows: anti-AGR2 (EPR3278/ab76473), 1:20; anti-PDI 
pAb, 1:25; anti-ERp29 (ab11420), 1:500.  
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2.3 Cell culture 
OE19 (JROECL19) and OE33 (JROECL33) cells were obtained from ECACC, both at 
passage number p6. The OE19 cell line was established from an adenocarcinoma of 
gastric cardia/oesophageal gastric junction from a 72-year-old male patient. The 
tumor was identified as pathological stage III (UICC) and showed moderate 
differentiation. The OE33 cell line was established from an adenocarcinoma of the 
lower oesophagus (Barrett’s metaplasia) from a 73-year-old female patient. The 
tumor from which the cells were taken was identified as pathological stage IIA (UICC) 
and showed poor differentiation. The OE cell lines were subcultured twice weekly in 
Rosewell Park Memorial Institute medium (RPMI) 1640 (Invitrogen) supplemented 
with fetal bovine serum (FBS) to a final concentration of 8%, 2mM glutamax 
(Invitrogen) and 100 µg/mL Penicillin/Streptomycin (Invitrogen).  
HT0180 cells were subcultured twice weekly in Dulbecco’s Modified Eagle’s Medium 
(DMEM, Gibco, Thermofisher Scientific) supplemented with with fetal bovine serum 
(FBS) to a final concentration of 8%, 2mM glutamax (Invitrogen) and 100 µg/mL 
Penicillin/Streptomycin (Invitrogen).  
All cell lines were kept in a humidified incubator at 37°C and 5% CO2. Treatments 
were carried out when the cells reached ~70% confluence, in 6 cm dishes. 
2.4 Immunofluorescence 
OE19 cells grown on coverslips were fixed with 4% paraformaldehyde (PFA) (agar 
scientific) in phosphate buffered saline with magnesium and calcium (PBS++) for 10 
min, free aldehyde groups were quenched with 50 mM ammonium chloride in PBS++ 
for 10 min then the cells were permeabilised with 0.1% Triton X-100 in PBS++ for 10 
min. Samples were then blocked in 0.2% bovine serum albumin (BSA) in PBS++ twice 
for 5 min each then incubated with 25 µL primary antibody solution, diluted in 0.2% 
BSA in PBS++, for either 1 hour (PDI) or overnight (AGR2, PrdxIV). Following primary 
incubation, samples were washed three times with PBS++ then incubated with 
secondary antibody solution, diluted in 0.2% BSA in PBS++, for 25 mins in the dark. 
Following secondary incubation, samples were washed twice with BSA, twice with 
PBS++ then incubated with 50 µL 5 µg/mL DAPI solution for 5 mins, rinsed briefly in 
PBS++ and dH2O then mounted on microscope slides with Vectashield mounting 
medium (vectorlabs). Before imaging slides were left at 4°C overnight to allow the 
Vectashield to set. The slides were imaged on either a brightfield fluorescence 
microscope (Zeiss ApoTome) or a confocal microscope (Zeiss 880). When using two 
primary antibodies for co-staining both were applied simultaneously.  
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2.5 Preparation of cell culture medium for treatment 
Stock solids of the chemicals, diamide, bile acids and thapsigargin were dissolved in 
dH2O to produce stock solutions that were aliquoted and frozen at -20°C. 
Immediately prior to treatment stock solutions were defrosted and an appropriate 
volume was added to an aliquot of sterile RPMI media to give the desired final 
concentration. If media was required at a specific pH then media was aliquoted, 
adjusted to the desired pH dropwise with HCl or NaOH and tested with a calibrated 
pH meter. The pH-adjusted media was then sterilised by filtration through a 0.22 µm 
syringe filter (MILLIPORE) and stored at 4°C until needed. 
2.6 Cell treatments 
Cells were treated with fresh RPMI media (as described above) supplemented with 
the desired chemical and concentration and returned to the 37°C incubator for the 
required time course. Following treatment cells were washed twice with phosphate 
buffered saline (PBS) for 5 minutes. The first PBS wash was supplemented with 20 
mM N-ethylmaleimide (NEM) in experiments using NEM. Cells were lysed 
immediately after treatment. 
2.7 Cell lysis 
Cells were lysed on ice in 300 µl of MNT lysis buffer (20 mM 4-
morpholineethanesulfonic acid, 30 mM Tris, 100 mM NaCl, pH 7.4) with 1% Triton X-
100, supplemented with 10 µg/ml each of the protease inhibitors chymostatin, 
leupeptin, antipain, and pepstatin A. Lysis buffer also contained 20 mM NEM in 
experiments using NEM. Lysed cells were scraped and the lysates were collected in 
Eppendorf tubes. The cell nuclei were removed by centrifugation at 16,100g 
(Eppendorf microcentrifuge) for 10 min at 4°C and the supernatants were collected 
in fresh Eppendorf tubes and flash frozen in liquid nitrogen and stored at -20°C. 
2.8 Protein determination 
Protein concentrations for equal loading were determined using the Bio-Rad Protein 
Assay procedure with BSA used as a standard. Standards were produced by 
combining the Bradford dye with dH2O, HCl, BSA and lysis buffer. A 1 mg/mL stock 
solution of BSA was diluted in lysis buffer to produce final concentrations ranging 
from 0-10 µg/mL. Samples were produced by combining the Bradford dye with dH2O, 
HCl, lysis buffer and 2 µL of lysate. Mixtures were left for 10 minutes then vortexed 
and their absorbances measured at 595 nm in an Eppendorf Biophotometer. 
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2.9 SDS-PAGE 
For protein detection, samples were analysed under either reducing or non-reducing 
conditions in SDS-PAGE. Samples for SDS-PAGE were prepared by adding 2x Laemmli 
sample buffer to cell lysates. For samples ran under reducing conditions 50 mM DTT 
was also added. To denature the proteins within the sample they were heated at 
95°C for 5 mins, then centrifuged at 16,100 g for 5 mins to collect the liquid at the 
bottom of the tube. Prepared samples were analysed using either 8%, 10% or 12% 
acrylamide gels. The resolving gel was comprised of: acrylamide (variable 
percentage) (Severn Biotech), 0.375 M Tris (pH 8.8), 0.1% SDS, 0.1% ammonium 
persulphate (APS) and 0.04% N,N,N’,N’-Tetramethylethylenediamine (TEMED). The 
stacking gel was comprised of: 5% acrylamide, 0.125 M Tris (pH 6.8), 0.1% SDS, 
0.075% APS, 0.1% TEMED. 
Acrylamide gel were cast in the Hoefer mini gel casting system. The resolving gel was 
first cast and left to polymerise, with water to cover the gel. The water was then 
removed and replaced with the stacking gel, followed by insertion of either a 10 well 
or a 15 well comb. Once the gel fully polymerised samples were loaded alongside a 
protein stained marker (Bio-Rad). Gels were run at 10-50 mA for approximately one 
hour in a Hoefer mighty small II mini vertical electrophoresis unit containing 1x Tris-
Glycine buffer (25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3). Analysis was done 
either via western blotting or Coomassie blue staining. 
2.10 Coomassie gel staining 
After SDS-PAGE, gels were fixed in a fixing solution (7% acetic acid and 40% methanol 
in dH2O) for 10 minutes. To stain the gels, fixing solution was removed and the 
Coomassie stain was applied (80% Brilliant blue G-colloidal concentrate in methanol). 
Staining took place overnight with gels placed on a rocker. To destain the gels, the 
first destaining solution (25% methanol, 10% acetic acid in dH2O) was applied for 10 
minutes, followed by the second destaining solution (25% methanol in dH2O) which 
was applied for another 10 minutes. Gels were scanned into an office computer. 
2.11 Western blotting 
Following SDS-PAGE separation, proteins were transferred to polyvinylidene fluoride 
(PVDF) membrane. For transfer, membranes were first submerged in methanol for 
20 seconds to activate them, then placed in transfer buffer (25 mM Tris base, 190 
mM glycine and 20% methanol in dH2O) and transferred at either 150 mA for 2 hours 
or at 30V overnight. Membranes were then blocked in 5% non-fat dry milk in TBS-T 
(Tris-buffered saline (10 mM Tris base, 70 mM NaCl, 1.34 mM KCl) containing 0.1% 
Tween 20) for 1h at room temperature. Membranes were washed 5 times with TBS-
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T before either a 1-hour incubation at RT or an overnight incubation at 4°C with 
primary antibody (dependent on antibody), followed by another 5 washes and 
incubation for 1 hour at room temperature with either swine anti-rabbit HRP (SARPO) 
or goat anti-mouse HRP (GAMPO). Antibody concentrations are listed in section 2.2. 
To visualise protein localisation, 500 µL of enhanced chemiluminescence (ECL) 
solution per membrane was used. Membranes were exposed to photographic light 
sensitive film in a dark room and subsequently developed in an X-ray developer 
machine (XOMAT). 
Western blot quantification through densitometry was performed on scanned 
immunoblot images with the ImageJ image processing program.  
2.12 Immunoprecipitation 
Immunoprecipitation of target proteins was performed using Protein A-Sepharose 
beads (Sigma). Protein A-Sepharose beads were incubated with the indicated 
antibodies (concentrations in section 2.2) for 1h at 4°C followed by three washes with 
lysis buffer (20 mM 4-morpholineethanesulfonic acid, 30 mM Tris, 100 mM NaCl, pH 
7.4) with 1% Triton X-100. The bead-antibody mixture was then incubated with 200 
µl cell lysate overnight at 4°C and washed with lysis buffer another five times, keeping 
the supernatant from the first wash for Western blotting analysis. The last four of 
these washes were performed without 1% Triton X-100 when preparing samples for 
mass spectrometry. Samples were eluted using either 50 µl Laemmli 2x sample buffer 
if intended for Western blotting or 30 µl elution buffer (4% SDS, 100 mM DTT, 100 
mM Tris-Cl) if intended for mass spectrometry. In each experiment an IgG control 
was performed where Protein A-Sepharose beads and antibody were incubated 
together without cell lysate to identify any signal arising that was not directly 
resulting from the cell lysate, such as antibody-antibody interactions. 
2.13 Proteomics 
Immunoprecipitated samples, eluted in elution buffer as described above, require 
digestion in short peptides before they are suitable for analysis by mass 
spectrometry. The Filter Aided Sample Prep (FASP) Protein Digestion Kit from 
expedeon (44250) was used for this purpose. Of the 30 µL of elute sample produced 
from the IP, 2 µL was used in a Bradford protein determination assay as information 
about the amount of total protein in each sample was required for MS analysis. 
Immediately prior to FASP digestion DTT was added to samples for a final 
concentration of 5 mM. FASP digestion was performed by adding 28 µL of protein 
extract to a spin filter followed by washing in urea to reduce the concentration of 
SDS in the filter. Samples were then alkylated with iodoacetamide and transferred to 
28 
 
ammonium bicarbonate for enzymatic digestion with trypsin (used at a 1:100 
enzyme-to-protein ratio) and acidified with trifluoroacetic acid (TFA).  
Peptides generated by FASP digestion were analysed by data-dependent LC-MS/MS 
on a TripleTOF 6600 mass spectrometer (Sciex) linked to an Eksigent 425 liquid 
chromatography system via a Sciex Nano-spray III source. The peptide mass in each 
of the final FASP-eluates was assumed to be the same as the mass of protein 
digested. Final eluates were freeze-dried and the residue re-suspended at 1 µg/µl in 
2% ACN, 0.1% formic acid. Nano-flow chromatographic separation of peptides used 
a trap-and-elute method with an Acquity M-class Symmetry C18 Trap column, 100Å, 
5 µm, 180 µm x 20 mm (Waters), and a PicoFrit packed emitter column 75 µm x 250 
mm - 10 µm tip - containing Reprosil-PUR 3µm (New Objective). One microgram 
peptide samples were transferred onto the trap column within a 25 µL volume of 
0.1% formic acid at 5 µL/min before injection-valve-switching and running of the 
following gradient at 300 nL/min. Buffer A = 0.1% formic acid in water, buffer B 0.1% 
formic acid in ACN. Sequential linear gradients of 1 to 28% B over 50 minutes and 28 
to 80% B over 5 minutes were followed by a 5-minute column wash in 80% B. Return 
to 1% B was over 3 minutes and the column was then re-equilibrated in this buffer 
for 27 minutes. 
Data-dependent top-30 MS-MS acquisition started immediately upon gradient 
initiation and was for 80 minutes. Throughout this period, precursor-ion scans (400 
to 1600 m/z) of 250 ms enabled selection of up to 30 multiply-charged ions for CID 
fragmentation and MS/MS spectrum acquisition (m/z 100-1600) for 33 ms. Rolling 
precursor exclusion of 15 seconds was applied throughout to limit multiple 
fragmentation of the same peptide. 
Precursor- and fragment-ion lists in mgf format were generated from wiff format raw 
MS data-files using MSConvert, available as part of the ProteoWizard software suite. 
Protein identification used the database search engine Mascot 2.5.1. and a database 
containing Uniprot human db download (6-4-17) plus 9 protease/GFP/YFP 
sequences. The peptide false discovery rate from a target decoy database was set at 
≤1% and a filter of >1 unique peptide sequence per protein applied.  
2.14 Transfection 
Transfection of OE19 cells with Myc-tagged ERp29 cDNA (OriGene, CAT#: RC210918) 
was performed following the Lipofectamine 3000 Reagent Protocol from 
ThermoFisher Scientific. OE19 cells were grown to ~70% confluence and 
transfections were performed under sterile conditions within a flow hood. Ero1α 
cDNA was used as a positive control as this had previously been tested in our 
laboratory and a mock transfection without cDNA added was used as a negative 
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control. Prior to transfection, 5 µL of lipofectamine was added to 125 µL of Opti-MEM 
and vortexed to mix. Additionally, 5 µL of P3000 and either 12.5 µL or 25 µL of ERp29 
cDNA (1.25 µL for Ero1α cDNA, 0 µL for mock) was added to another 125 µL of Opti-
MEM. These two solutions were mixed together and allowed to incubate at RT for 10 
minutes, during which time the cells were washed with 2 mL PBS twice. The DNA-
lipofectamine-Opti-MEM mixture was then added to the cells, followed by an 
additional 250 µL of Opti-MEM and incubation for 1 hour at 37°C. Following this, an 
extra 1 mL of Opti-MEM was added to each dish and cells were incubated at 37°C for 
24 hours to allow the transfection to take place. Cells were then washed in PBS twice 
and lysed in MNT lysis buffer as described previously. 
 
 
 
 
 
 
 
 
 
 
2.15 Deglycosylation 
Deglycosylation was attempted as a method for more clearly visualising mucins on 
an SDS-PAGE gel. To achieve this the New England Biolabs PNGase F protocol was 
used. Lysates were prepared as described previously, without treatment with NEM, 
and protein concentrations were determined via Bradford assay. Both denaturing 
reaction conditions and non-denaturing reaction conditions were tested to allow 
comparison and to determine the extent of reaction completion.  
Figure 4: Circular map for the RC210918 cDNA construct.  
Transfection of OE19 cells was attempted through the use of the RC210918 cDNA 
construct containing a ERp29 sequence with a Myc-tag at its C-terminal and a 
kanamycin resistance gene. 
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Denaturing deglycosylation was achieved by combining cell lysates and Glycoprotein 
Denaturing Buffer, heating the mixture at 100°C for 10 minutes followed by chilling 
on ice and centrifuging to collect the solution. This was then supplemented with 
GlycoBuffer 2, 10% NP-40 and PNGase F and incubated at 37°C for 1 hour. Non-
denaturing deglycosylation was achieved by combining cell lysate, GlycoBuffer 2 and 
PNGase F and incubating the reaction at 37°C for 4 hours. Samples were then 
analysed by reducing western blotting as described previously. 
2.16 Alcian Blue gel staining 
The Alcian Blue gel staining method was used in an attempt to visualise mucins on an 
SDS-PAGE gel. After samples were separated on an SDS-PAGE gel, as described 
previously, gels were moved to a pH 2.5, 0.5% Alcian Blue solution in 2% aqueous 
acetic acid and left to stain for 45 minutes. This was followed by a destain in 2% 
aqueous acetic acid for 15 minutes. Gels were scanned into an office computer. 
2.17 Partial trypsinisation 
OE19 lysates were subjected to limited proteolysis through the addition of varying 
trypsin concentrations. A stock solution of trypsin was added to each lysate to 
achieve final trypsin concentrations of 0, 0.25, 1.25 and 2.5 µg/mL. Lysates were 
incubated for 30 minutes at 4°C to allow for digestion, followed by digestion 
termination with the addition of soybean trypsin inhibitor (SBTI) for a final 
concentration of 200 µg/mL. Lysates were then analysed on 8% acrylamide gels by 
SDS-PAGE and western blotting as described previously.  
2.18 Mouse stomach lysis 
Male mice aged 8-12 weeks were sacrificed in accordance with the Animals (Scientific 
Procedures) Act (1986) by trained personnel in the Life Sciences Support Unit at 
Durham University. 
After removal from the body of the mouse the stomach was cut into four similarly 
sized pieces and thoroughly cleaned in PBS. Each piece of the mouse stomach was 
treated in either RPMI media containing 5 mM diamide or diamide free media for 5 
minutes, and subsequently washed in either PBS or PBS supplemented with 20 mM 
NEM for 5 minutes. This produced four different conditions. All pieces were then 
washed in PBS for 5 minutes and cells were scraped from the tissue with the use of a 
scalpel. Solutions containing the cells were centrifuged at 1200 rpm for 5 minutes to 
pellet the cells. The PBS supernatant was removed and replaced with 300 µL MNT 
lysis buffer (containing 20 mM NEM in NEM treated samples). This solution was left 
for 5 minutes at 4°C, centrifuged at 16,100 g for 10 min at 4°C and the supernatants 
were collected in fresh Eppendorf tubes and flash frozen in liquid nitrogen and stored 
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at -20°C. Samples were analysed by SDS-PAGE and western blotting as described in 
sections 2.9 & 2.11. 
2.19 Immunohistochemistry 
Paraffinized oesophageal tissue sections were provided by YKS Viswanath and Julie 
Walker, James Cook University Hospital, Middlesbrough and stained for AGR2 using 
the 3,3’-dianimobenzidine (DAB) staining method.  
Tissue sections embedded in paraffin were incubated at 50°C overnight prior to 
staining. Sections were deparaffinised with two 7-minute washes in Histoclear, one 
7-minute wash in 100% ethanol, one 5-minute wash in 95% ethanol and finally one 
5-minute wash in 70% ethanol. Sections were then hydrated in dH2O for 3 minutes. 
Antigen retrieval was achieved by treating the sections with 3% H2O2 in MeOH for 15 
min followed by 20 min in 10 mM Na-citrate (pH 6.0) at 90°C. Slides were then cooled 
on ice, followed by a 5-minute wash in 0.2% BSA in PBS and a 30-minute blocking 
incubation in 0.2% BSA + 5% normal goat serum (DAKO, X0907) in PBS. Long 
incubations such as this blocking step were performed in a moist chamber to reduce 
evaporation. Sections were then incubated with an AGR2 mAb (ab76473) at a 1:250 
dilution in PBS + 0.2% BSA + 2% normal goat serum for 1-hour RT. After primary 
incubation, sections were washed in 0.2% BSA in PBS for 5 minutes, followed by a 45-
minute RT incubation with secondary antibody goat anti-mouse/rabbit biotin (made 
by mixing 2 mL PBS with 20 µL reagent C from Dako kit, K0492). After which they 
were again washed in 0.2% BSA in PBS for 5 minutes and then incubated with a 
reagent A/B mixture (made by mixing 2 mL PBS with 20 µL reagent A and 20 µL 
reagent B) for 30 minutes RT. This mixture required making 15 minutes before use. 
For the next step a DAB solution was required, comprising of 5 mL PBS, a H2O2 tablet 
and a DAB tablet. This solution was applied to the sections and they were allowed to 
develop before submersion in dH2O to stop development. Slides were then stained 
with haematoxylin for 4 minutes, followed rinsing in dH2O, 1% HCl in MeOH, dH2O 
again, tap water, 70% EtOH, 95% EtOH, a 5-minute wash in 100% EtOH, two 7-minute 
washes in Histoclear and finally mounting in DPX (Agar Scientific, R1340). Slides were 
imaged with a Leica ICC50 microscope. 
2.20 Alcian Blue tissue section staining 
Alcian Blue was also used on the paraffinized oesophageal tissue sections as a stain 
for mucin. Tissue sections embedded in paraffin were incubated at 50°C overnight 
prior to staining. Sections were deparaffinised with two 7-minute washes in 
Histoclear, one 7-minute wash in 100% ethanol, one 5-minute wash in 95% ethanol 
and finally one 5-minute wash in 70% ethanol. Sections were then hydrated in dH2O 
for 3 minutes, rinsed in dH2O, washed in 3% acetic acid for 3 minutes then stained 
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with a pH 2.5, 0.5% Alcian Blue solution in 2% aqueous acetic acid for 30 minutes. 
Following staining, sections were rinsed in a gentle flow of tap water for 10 minutes 
and then rinsed briefly in dH2O. Slides were then stained with haematoxylin for 6 
minutes, then subsequently rinsed in dH2O, 1% HCl in MeOH, dH2O again, tap water, 
70% EtOH, 95% EtOH, a 5-minute wash in 100% EtOH, two 7-minute washes in 
Histoclear and finally mounting in DPX (Agar Scientific, R1340). Slides were imaged 
with a Leica ICC50 microscope. 
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3 Results 
3.1 AGR2 expression and localisation in OE19 cells 
Barrett’s Oesophagus is a pre-malignant condition leading to oesophageal 
adenocarcinoma in which the appearance of the oesophageal epithelium changes to 
more resemble that of the stomach. With this metaplasia comes the induction of 
mucin synthesis, mucous production and the derepression of the mucin specific 
protein disulphide isomerase AGR2 (Pohler et al., 2004). In order to study AGR2’s role 
within Barrett’s Oesophagus, the OE19 oesophageal adenocarcinoma immortalised 
cell line was chosen. Previous work in the laboratory had suggested that AGR2 was 
expressed in this oesophageal cell line (Simpson and Benham, unpublished data). 
To check expression of AGR2 in this cell line and to determine the subcellular 
localisation of AGR2 within OE19 cells, immunofluorescence was performed. Cells 
were grown on coverslips, fixed with 4% PFA in PBS++, permeabilised with Triton X-
100 and stained with either the AGR2 D9V2F rabbit mAb or a PDI pAb, and co-stained 
with DAPI. The secondary antibody used was the donkey anti-rabbit Alexa Fluor 594 
(red). Images were taken on a Zeiss Apitome Brightfield microscope. As PDI is known 
to be localised and retained in the ER, a polyclonal PDI antibody was used to stain 
the ER of the OE19 cells. This visualisation of the ER can then be used as a point of 
reference when observing the localisation of other proteins via immunofluorescence, 
for example AGR2. 
PDI localisation in OE19 cells is shown in Figure 5 as a ring around the DAPI (blue) 
stained nuclei. Cells stained with the AGR2 mAb shown in Figure 5 demonstrate the 
strong expression of AGR2 in this cell line. These cells had a similar pattern of AGR2 
localisation to the PDI stained cells, implying they are both localised to the ER, 
although higher resolution images and co-staining would be required to confirm this 
observation. 
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Figure 5: PDI expression and localization in OE19 cells. 
OE19 cells were stained with a polyclonal PDI antibody and anti-rabbit Alexa Fluor 594 in 
order to observe expression and ER localization. DAPI (blue) was used to stain the nuclei 
of cells. Perinuclear expression of PDI (red) indicates ER localisation. Images were taken 
on a Zeiss ApoTome brightfield microscope. (A) x20 magnification. (B) x63 magnification. 
Figure 6: AGR2 expression and localization in OE19 cells. 
OE19 cells were stained with the D9V2F AGR2 mAb and anti-rabbit Alexa Fluor 594 in 
order to observe expression and subcellular localization. DAPI (blue) was used to stain the 
nuclei of cells. Similarly to PDI expression, AGR2 expression displays perinuclear 
localisation, indicating ER localisation. Images were taken on a Zeiss ApoTome brightfield 
microscope. (A) x20 magnification. (B) x63 magnification. 
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Figure 7: No primary antibody on OE19 cells. 
OE19 cells only stained with anti-rabbit Alexa Fluor 594. No primary antibody was used. 
Images were taken on a Zeiss ApoTome brightfield microscope. (A) x20 magnification. 
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Although images taken on the Zeiss ApoTome microscope indicate perinuclear 
expression of AGR2, this could not be confirmed due to low image resolution. 
Therefore, it was decided to switch the microscope to a laser-scanning confocal 
microscope. Confocal microscopy makes use of a pinhole between the sample and 
detector, blocking out-of-focus light and allowing the image to be acquired from a 
single focal plane. This technique allows much higher resolutions than standard 
brightfield imaging and is better suited to the OE19 cells as they tend to adhere to 
each other and form masses of cells rather than spreading out and creating a flat 
monolayer.  
The Zeiss LSM 880 Confocal Microscope was used to obtain higher resolution images, 
as shown in Figure 8. In a separate experiment to the one described previously, cells 
were again grown on coverslips, fixed with 4% PFA in PBS++, permeabilised with 
Triton X-100 and stained with either the AGR2 D9V2F rabbit mAb or a PDI pAb, and 
co-stained with DAPI. The secondary antibody used was donkey anti-rabbit Alexa 
Fluor 594 (red). Perinuclear staining can be observed clearly when staining for PDI 
(Figure 8A), and AGR2 (Figure 8B), which again shows a similar profile of expression 
localisation when compared to PDI, indicating that in OE19 cells AGR2 is found within 
the ER. 
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Figure 8: Expression and localization of PDI and AGR2 in OE19 cells. 
(A) Cells stained with polyclonal PDI show the typical ER expression within OE19 cells. (B) 
Cells stained with the D9V2F AGR2 mAb showed subcellular localisation of AGR2 within 
OE19 cells. (C) OE19 cells stained with only anti-rabbit Alexa Fluor 594 (no primary 
antibody). Images were taken on a Zeiss LSM 880 confocal microscope at x63 
magnification. 
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3.2 The effect of redox on AGR2 complex formation 
Experimental work performed in the lab previously by Simpson and Benham 
(unpublished data) showed evidence that, in the OE19 oesophageal adenocarcinoma 
cell line, treatment of the cells with DTT (5 mM) - a reducing agent and ER stress 
inducer – altered the ability of AGR2 to form protein complexes. In these experiments 
the alkylating agent N-ethylmaleimide (NEM) was used to sequester free thiol groups 
and therefore trap disulphide bonds in their native conformation, allowing 
visualisation of disulphide bond dependent complexes through non-reducing 
western blotting. These observations indicated that AGR2, in oesophageal 
adenocarcinoma, forms complexes that are either redox dependent, indicating that 
these interactions require disulphide bonds, ER stress dependent and the changes 
observed are due to the extra stress put on the ER by the addition of DTT, or a 
combination of the two. 
To test whether the complexes previously observed are redox dependent, the 
oxidising agent diamide was chosen. As an oxidising agent diamide will alter the 
redox state of a living cell it is added to, inducing a change to more oxidising 
conditions and therefore promote the formation of disulphide bonds. If the 
complexes AGR2 forms with partner proteins are redox dependent, as was theorised 
by Simpson and Benham, then diamide should promote AGR2 interactions and 
induce complex formation, and these complexes should be visible through non-
reducing western blotting. 
Diamide treatments were performed on the OE19 cell line using 5 mM diamide in 
RPMI medium for either 0, 5 or 10 minutes, followed by washing with PBS 
supplemented with 20 mM NEM to trap disulphide bonds. Lysates were made using 
an MNT lysis buffer supplemented with 20 mM NEM and the lysates were analysed 
by SDS-PAGE and western blotting using the D9V2F AGR2 mAb. The results of this 
experiment (Figure 9) show an immediate induction of AGR2 complexes under non-
reducing conditions when diamide is present in the treatment. Multiple overlapping 
bands appear at higher molecular weights along with a clear band appearing at ~37 
kDa which is assumed to be AGR2 in its homodimeric form; this is consistent with the 
literature (Ryu et al., 2013). This result clearly shows that AGR2 can form redox 
dependent and therefore disulphide bond dependent complexes, and that these 
complexes can be trapped with NEM for later analysis. 
The combination of diamide to induce disulphide bond formation and NEM to trap 
and prevent disulphide bonds reshuffling demonstrates a method for trapping 
disulphide dependent interactions that will be used later in this project. 
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After inducing AGR2 complexes with diamide, the question was asked whether these 
complexes are stable or transient. To determine whether the induction of AGR2 
complexes by diamide could be reversed, a recovery experiment was performed. 
Following a 5-minute treatment with diamide, OE19 cells were exposed to diamide-
free media for varying lengths of time before NEM treatment and lysis as previously 
described. Figure 9C shows a western blotting analysis of these treatments.  
Complexes were again induced rapidly after the addition of diamide to the media. A 
possible transfer inefficiency of higher molecular weight complexes from the 
acrylamide gel to the PVDF membrane may be the reason why bands appear fainter 
in the 5-minute recovery lane (labelled 5r in Figure 9C). Despite that, it is still clear 
that some bands disappeared after recovery and some persisted. Most notable is the 
single well-defined band that appeared above the dimer band in the 5-minute 
treatment but was then absent in the recovery lanes. This is likely to be the same 
band seen in the 5-minute treatment but absent from the 10-minute treatment in 
Figure 9A.  
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Figure 9: Diamide treatment promotes AGR2 complex formation in OE19 cells. 
(A) OE19 cells, treated with 5mM diamide for either 0, 5 or 10 minutes, were lysed and run on a 12% poly-acrylamide gel, transferred to a PVDF membrane 
and probed using the D9V2F AGR2 mAb. Complexes appear in diamide treated lanes under non-reducing conditions. (B) β-actin loading control for diamide 
treatment samples. (C) OE19 cells treated with diamide as before, but also allowed to recover for 5, 10 and 20 minutes prior to lysis. Recovery lanes show 
most complexes persist, however some (*) were reduced after recovery. (D) β-actin loading control for diamide treatment and recovery samples. Dia = 
diamide treatment. Molecular weight markers were used, as marked on the left of the gels, and were in kDa. 
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3.3 The effect of ER stress on AGR2 complex formation 
Previous work by Simpson and Benham showed evidence that AGR2 complex 
formation, in OE19 cells, is affected by DTT treatment (unpublished). DTT is a known 
inducer of ER stress so one possibility is that the change in AGR2 complex formation 
observed after DTT treatment could be due to the ER stress caused by DTT treatment 
on OE19 cells. In order to test the effect ER stress had on AGR2 complex formation, 
independent of the redox changes induced by DTT, other non-redox-active inducers 
of ER stress were tested. Thapsigargin was chosen as it is a potent inducer of ER stress 
and it is also not redox-active. 
OE19 cells were treated with media containing 2 µM thapsigargin for 0, 30 and 60 
minutes and 6 hours, treated with 20 mM NEM in PBS and lysed in MNT lysis buffer 
containing 20 mM NEM. Lysates were analysed via SDS-PAGE and western blotting 
using the D9V2F AGR2 mAb (Figure 10A). A diamide treated OE19 sample was loaded 
onto the gel as a positive control for AGR2 complexes. Reducing samples were also 
probed with a P-eIF2α antibody to test for the induction of ER stress (Figure 10C). 
After 60 minutes thapsigargin treatment a signal could be seen when using a P-eIF2 
antibody, and a stronger signal seen after 360 minutes, indicating ER stress was being 
inducted. 
No complexes were observed in any of the thapsigargin treated samples when 
immunostaining for AGR2, indicating that there was no strong induction of AGR2 
complexes. However, the diamide treated sample also did not show the same strong 
induction of higher molecular weight bands as shown in previous experiments. This 
may be due to an issue in transferring higher molecular weight complexes to the 
PVDF membrane. Therefore, it cannot be said definitively whether thapsigargin has 
an effect on AGR2 complex formation. 
It was speculated that the conditions known to induce the transition from normal 
oesophageal epithelium to Barrett’s epithelium may also play a role in AGR2 complex 
formation. During the transition into Barrett’s epithelium, gastric reflux exposes 
oesophageal cells to low pH and a plethora of stomach bile acids. These conditions 
have previously been shown to induce oxidative stress and oxidative DNA damage in 
Barrett’s oesophagus cells, and are theorised to be behind the development of 
Barrett’s oesophagus and subsequent tumour progression (Dvorak et al., 2007). 
Therefore, it was decided to test the effect of low pH in combination with bile acids 
on AGR2 complex formation in OE19 cells. 
A bile acid cocktail, as described in Dvorak et al., 2007 and also the materials and 
methods section of this thesis, was added to RPMI media and acidified to pH 4. OE19 
cells were treated with this media for 0, 5 and 10 minutes as well as a longer 6-hour 
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time course before treatment with NEM in PBS and lysis with an MNT lysis buffer 
supplemented with NEM. Lysates were analysed by SDS-PAGE and western blotting 
using the D9V2F AGR2 mAb. A diamide treated OE19 sample was loaded onto each 
gel as a positive control for AGR2 complexes. Coomassie gel staining was also 
performed on separate gels alongside western blots as a secondary loading control. 
Coomassie stained gels are shown in Figure 11A and B. 
Western blotting results from samples treated with low pH media only (Figure 11C) 
showed no evidence of AGR2 complex formation. Samples treated with low pH media 
supplemented with bile acids (Figure 11D) did however show some evidence of AGR2 
complex formation despite excessive background signal on the blot that obscured 
some of the non-reducing samples in the 5 and 10 min lanes. Some, complexes also 
appeared in the reducing lane of the 10 min sample, possibly due to ineffective 
reducing agent or contamination from the diamide treated lane. Overall, low pH and 
bile acid treatments suggest that the bile acid environment does not promote the 
formation of disulphide dependent-complexes between AGR2 and itself or partner 
proteins; however, if more time was available, it would be worth extending this 
analysis to a wider range of bile acid combinations with additional controls. 
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Figure 10: The effect of thapsigargin on AGR2 complex formation in OE19 cells.  
(A) OE19 cells treated with 2 µM thapsigargin for 0, 30, 60 and 360 minutes showed no 
visible changes in disulphide-dependent complex formation under non-reducing 
conditions. An OE19 lysate treated with 5mM diamide for 5 minutes (as described in Figure 
9) and ran under non-reducing conditions was used as a positive control for complexes 
(central lane). (B) β-actin loading control for thapsigargin treated samples. (C) Reducing 
thapsigargin treated samples were probed with an antibody for PeIF2α as this is a marker 
for ER stress. Weak bands appeared in lanes with longer treatments indicating the 
thapsigargin caused ER stress in the cells. R = gel ran under reducing conditions. NR = gel 
ran under non-reducing conditions. Molecular weight markers were used, as marked on 
the left of the gels, and were in kDa. 
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Figure 11: The effect of low pH and bile acids on AGR2 complex formation in OE19 cells.  
OE19 cells were treated with pH 4 RPMI media supplemented with a cocktail of bile acids to test their effect on AGR2 complex formation. Coomassie 
stained SDS-PAGE gels showed that protein composition was not grossly altered by the treatments and serve as a protein recovery control. A single diamide 
treated sample was loaded onto each gel as a positive control for AGR2 complexes. (A) Coomassie gel showing samples treated with low pH media without 
bile acids. (B) Coomassie gel showing samples treated with low pH media and with bile acids. (C) Western blot showing samples treated with low pH media 
without bile acids probed for AGR2. (D) Western blot showing samples treated with low pH media with bile acids probed for AGR2. Some complexes 
appeared, although they were obscured by background signal. (E) β-actin loading control for samples treated with low pH media. (F) β-actin loading control 
for samples treated with low pH media supplemented with bile acids. R = gel ran under reducing conditions. NR = gel ran under non-reducing conditions. 
Molecular weight markers were used, as marked on the left of the gels, and were in kDa. 
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3.4 Identification of novel AGR2 interacting proteins 
The western blotting results shown in Figure 9 demonstrate results obtained from 
using a trapping approach for retaining disulphide bonded complexes in the presence 
of diamide and NEM. Having demonstrated the effectiveness of this trapping 
approach through western blotting it was decided to use proteomic analysis to 
determine the identity of the proteins with which AGR2 interacted. 
Immunoprecipitation was used to separate AGR2 and its interactors from the 
remaining cell lysate, and mass spectrometry was employed to identify the proteins 
isolated by immunoprecipitation. However, before carrying out mass spectrometry 
analysis, immunoprecipitation was validated in our system with western blotting 
analysis. 
An independent AGR2 antibody, the rabbit monoclonal anti-AGR2 
(EPR3278/ab76473) antibody, was acquired for immunoprecipitation for two 
reasons. Firstly, the D9V2F AGR2 antibody did not support IP applications, and 
secondly, two different species of AGR2 antibodies are required to verify the 
presence of AGR2 in an AGR2 immunoprecipitated sample analysed by western 
blotting. 
Immunoprecipitation was first carried out on fresh OE19 lysates, without treatment 
with diamide or NEM. This was to test the capability and efficiency of the AGR2 
antibody to retain the AGR2 protein in our system. Two separate 
immunoprecipitations were performed, one with PDI and the other with AGR2. Both 
of these immunoprecipitations were then analysed via western blotting for both PDI 
and AGR2. 
OE19 cells were grown to ~90% confluency before lysis to ensure there were 
sufficient protein concentrations for immunoprecipitation. Immunoprecipitation was 
performed by incubating Protein A-Sepharose beads with either the AGR2 mAb 
ab76473 or the in-house generated PDI pAb to allow the antibodies to associate with 
the beads, followed by washing in MNT lysis buffer with 1% Triton X-100. The 
beads/antibody mix was then incubated with 200 µL of OE19 cell lysate for an 
appropriate period of time to allow the protein in the lysate to associate with the 
antibody. To serve as a negative control, one sample was immunoprecipitated with 
lysis buffer (added instead of lysate) at this step. Supernatant removed after 
incubation with the lysate was stored and ran on the SDS-PAGE gel alongside 
immunoprecipitate samples. The mixture was then washed again and eluted in 2x 
sample buffer. Samples were run on 12% SDS-PAGE gels under reducing conditions 
and analysed via western blotting using both the D9V2F AGR2 mAb and the PDI mAb 
RL90 (MA3-019). Results are shown in Figure 12. 
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Both blots showed strong staining in the 50 kDa region. This was due to the HRP-
conjugated secondary antibodies used in western blotting interacting with the IgG 
heavy chains of the antibodies used for immunoprecipitation. Supernatant samples 
taken after incubation with the lysate serves to show the effectiveness and efficiency 
of the immunoprecipitation. OE19 lysates immunoprecipitated with the ab76473 
AGR2 mAb and blotted back with the D9V2F AGR2 mAb showed a single band in the 
20 kDa region (Figure 12A). This band is the AGR2 monomer and its presence in both 
the OE19 lysate and the AGR2 immunoprecipitated eluate verifies that the AGR2 
immunoprecipitation was successful in retaining the AGR2 protein. Samples 
immunoprecipitated with a PDI pAb and blotted back with an AGR2 mAb (Figure 12A) 
showed no band in the 20 kDa AGR2 monomer region indicating that the PDI 
immunoprecipitation did not pull down the AGR2 protein and therefore an 
interaction was not observed. 
Figure 12B shows both immunoprecipitations blotted back with a PDI mAb. The PDI 
protein runs at ~50 kDa, similar to the IgG heavy chain. This overlapping range caused 
issues when interpreting the dense bands of the IgG heavy chain, which obscured the 
PDI signal. No clear PDI signals could be observed in Figure 12B and therefore no 
conclusion could be made as to the effectiveness of the immunoprecipitation. The 
identity of the dense bands that appeared in the OE19 lysate lane is uncertain but 
could be cross-linked PDI protein, or contamination from nuclear material. 
Having demonstrated the ability of the AGR2 mAb ab76473 to bind and retain AGR2 
during immunoprecipitation, it was decided to test AGR2 immunoprecipitation once 
more, this time in the presence of diamide and NEM. There is a possibility that 
diamide and/or NEM may interfere with the interaction between the AGR2 mAb and 
the AGR2 protein, therefore these conditions were tested first with western blotting 
before committing to mass spectrometry analysis. 
Cells grown to ~90% confluency were treated either with media containing 5 mM 
diamide or control media for 5 minutes, treated with 20 mM NEM and lysed in MNT 
lysis buffer containing 20 mM NEM. Immunoprecipitation was performed on these 
lysates as described previously. Immunoprecipitated samples were analysed via 
reducing western blotting with the D9V2F AGR2 mAb. 
Clear AGR2 monomer bands in the 20 kDa region could be seen in both the input and 
the AGR2 immunoprecipitated lanes and were entirely absent in the IgG lanes (Figure 
13), demonstrating that immunoprecipitation with the ab76473 AGR2 mAb in the 
presence of diamide and NEM was successful. AGR2 bands in the supernatant 
samples appeared weaker than those in the immunoprecipitated lanes, showing that 
the majority of the AGR2 protein in the lysates was retained throughout the 
immunoprecipitation. 
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Figure 12: OE19 cell lysates immunoprecipitated with PDI and AGR2 antibodies, blotted back for PDI and AGR2. 
OE19 cells were lysed and immunoprecipitated using either the AGR2 mAb ab76473 or an in-house generated PDI pAb. (A) Immunoprecipitated samples 
were blotted back with the D9V2F AGR2 mAb. Bands appearing in the 19 kDa range are the AGR2 monomer. The presence of the AGR2 monomer band in 
the OE19 positive IP:AGR2 eluate (black arrow) and absence in the OE19 negative eluate (white arrow) signifies that the immunoprecipitation was 
successful in extracting the AGR2 protein from the OE19 lysate. (B) Immunoprecipitated samples blotted back with the PDI mAb RL90. The PDI bands were 
obscured by IgG heavy chain. + = IP performed with OE19 lysate, - = IP performed without OE19 lysate, SN = supernatant (see IP method in section 2.12). 
Molecular weight markers were used, as marked on the left of the gels, and were in kDa. 
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Figure 13: OE19 immunoprecipitation with an AGR2 mAb in the presence of diamide 
and NEM. 
OE19 cells were treated with 5mM diamide and 20 mM NEM prior to lysis, 
immunoprecipitated with the AGR2 mAb EPR3278 and immunoblotted with the AGR2 
mAb D9V2F. Bands appearing at 19 kDa in the IP:AGR2 diamide positive (grey arrow) and 
negative lane (black arrow) demonstrates the retrieval of AGR2 was successful. + = IP 
performed with OE19 lysate, - = IP performed without OE19 lysate and dia = diamide 
treatment. Molecular weight markers were used, as marked on the left of the gel, and 
were in kDa. 
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After demonstrating that AGR2, in the presence of diamide and NEM, could be 
detected by immunoprecipitation, the next step was to prepare samples for mass 
spectrometry analysis. Inducing and retaining these AGR2 complexes and then 
subsequently isolating these complexes from the OE19 lysate provides a sample that 
in theory only contains AGR2 and the proteins it is interacting with. Proteomic 
analysis of the proteins contained within that sample should then reveal proteins 
involved in these AGR2 complexes, first observed in Figure 9. 
The immunoprecipitation conditions chosen for analysis by mass spectrometry were 
identical to those shown in Figure 13. The samples taken for analysis were: an OE19 
lysate treated with 5 mM diamide for 5 minutes prior to lysis, an OE19 lysate without 
diamide treatment and one immunoprecipitation with only lysis buffer to serve as a 
negative control. All samples were immunoprecipitated with the AGR2 mAb 
ab76473, all samples were supplemented with 20 mM NEM prior to lysis and all lysis 
buffer used contained 20 mM NEM. To prepare samples for mass spectrometry 
analysis the immunoprecipitation approach required slight adjustments. Removal of 
Triton X-100 from the final washes was required as it is not compatible with mass 
spectrometry. After immunoprecipitation, a Bradford protein determination assay 
was performed to divulge the protein concentrations in each sample and to check 
the success of the elution, followed by digestion with trypsin to produce peptide 
fragments suitable for detection by MS. This full process is detailed in Figure 14. 
Data received from the Protein Pilot software were in the form of protein summaries 
detailing the proteins peptides could be matched with reasonable confidence. In 
initial experiments, samples contained high quantities of keratins, a common 
contaminate detected in mass spectrometry analysis, although these numbers were 
significantly reduced after a more careful approach was adopted in a second round 
of sample preparation. As mentioned previously, one sample analysed by mass 
spectrometry was immunoprecipitated with lysis buffer instead of OE19 lysate to 
serve as a negative control. Any proteins detected in this control sample were 
immediately discounted from the protein summaries of samples 
immunoprecipitated with OE19 lysates. These proteins included keratins, 
immunoglobulins and cytoskeletal components. 
After subtracting hits also detected in the control sample and any extra keratins and 
obvious contaminants, proteins were selected that were deemed likely to be 
interacting with AGR2. These included proteins known to reside in the ER or secretory 
pathway and therefore would share the same intracellular localisation as AGR2. The 
most notable interactors were the mucins MUC5AC and MUC5B, which are known to 
be clients of AGR2, and lectins such as GAL4 and ZG16B, which may be involved in 
the AGR2-mucin interactions. Factors considered when evaluating the potential of a 
protein hit as a real AGR2 interactor included the peptide count – the number of 
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Figure 14: Schematic diagram describing a trapping and immunoprecipitation approach for detecting interacting proteins. 
OE19 cells grown to ~90% confluency were treated with or without diamide to induce disulphide bond formation and alkylated with NEM to trap disulphide 
bonds. Cells were lysed and the lysate were immunoprecipitated with an AGR2 mAb (ab76473) and protein was eluted in an SDS elution buffer. Samples 
were digested with trypsin via the FASP digestion method and analysed by ESI mass spectrometry to identify the peptide fragments present in the sample. 
These peptide fragments contained AGR2 and proteins locked in complex with AGR2. 
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peptides detected that matched the protein database sequence, and the unused 
value – a description of the uniqueness of the peptide sequences detected. All of the 
proteins described above had two or more peptide hits as well as unused values 
above zero, indicating that they were unlikely to be similar sequences of a different 
protein. Non-human sequences were screened out by the software. 
A curated list of proteins for each sample analysed by mass spectrometry are 
displayed in Tables 1-4. The unused score for a protein is a measure of the peptides 
detected during analysis that are unique to that protein, whereas the total score is a 
measure of the total peptides detected. Therefore, if a protein has an unused score 
lower than its total score it is possible that the peptides detected originated from 
another similar protein. Although included in the table, proteins with unused scores 
of 0 were not picked for further analysis. Percentage coverage (%Cov) was also 
displayed in the tables showing the percentage of the protein sequence that was 
covered by peptide matches. %Cov(50) and %Cov(95) refer to percentage coverage 
at 50% and 95% confidence respectively. %Cov was used as a measure of confidence 
that the protein was present in the sample, although ultimately proteins will low 
scores, such as calnexin (CNX), were investigated. Peptide counts were also used to 
determine protein confidence and initially a lower limit of 2 peptides was set. 
However, due to its known lectin binding abilities, ZG16B was investigated despite its 
peptide count of 1. 
AGR2 was successfully detected in all but the control samples providing a crucial 
point of verification that the immunoprecipitation was successful and specific. 
Several known AGR2 interacting proteins were also detected at high peptide counts, 
including the mucins MUC5AC and MUC5B, known clients of AGR2 (Schroeder et al., 
2012), as well as the ER resident chaperone BiP (Ryu et al., 2013). The presence of 
both MUC5AC and MUC5B at high peptide counts in the MS data suggests these are 
the primary clients of AGR2 in OE19 cells.  
Additionally, several other ER resident chaperones were detected, including: ERp29, 
PrdxIV, Ero1α, ERp44, ERp57, Calnexin, PDIA3 and P5. These proteins are all ER 
resident chaperones and therefore are highly likely to be involved in the interactions 
of AGR2. Also detected were the lectins GAL4 and ZG16B. Lectins are of particular 
interest as they may be involved in the AGR2-mucin interactions. MUC1, PDI and 
Prdx1 were all also returned in the protein summaries although all had unused values 
of zero indicating the peptides detected could be similar peptides from related 
proteins. Prdx1 is also not an ER resident protein and therefore is unlikely to be 
interacting with AGR2. 
To test and validate these interactions, antibodies specific to a selection of the 
proteins of interest were acquired where they were not already available and AGR2 
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immunoprecipitated samples were analysed by reducing western blotting using 
these new antibodies. MUC5AC was chosen as the mucin to test as it appeared at 
higher peptide counts overall, although MUC5B would also have been a suitable 
candidate.
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Table 1: List of protein identifications from the mass spectrometry analysis of 
an AGR2 immunoprecipitated, untreated OE19 lysate. 
 
Table 2: List of protein identifications from the mass spectrometry analysis of 
an AGR2 immunoprecipitated, diamide treated OE19 lysate. 
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Table 3: List of protein identifications from mass spectrometry analysis of an 
AGR2 immunoprecipitated, untreated OE19 lysate replicate. 
Table 4: List of protein identifications from the mass spectrometry analysis of 
an AGR2 immunoprecipitated, diamide treated OE19 lysate replicate. 
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3.5 Verification of the expression of AGR2 interactors 
Newly acquired antibodies for ERp29, GAL4, ZG16B and MUC5AC were tested with 
reducing western blotting of OE19 lysates to determine antibody effectiveness and 
protein expression (Figure 15). The ERp29 pAb (ab11420) showed a band in the 29 
kDa region in both lanes which was assumed to be monomeric ERp29, as well as other 
higher molecular weight bands, which are likely to be non-specific (Figure 15A). The 
GAL4 mAb (ab175185) showed strong expression in both lanes in the expected 36 
kDa region (Figure 15B). The ZG16B mAb (817310) did not show a band in the 
expected 22 kDa range yet did show a range of bands appearing at ~30-80 kDa (Figure 
15C). These signals were assumed to be caused by cross-reactivity and thus further 
analysis with this protein was halted. The MUC5AC mAb (ab198294) yielded a non-
distinct, smeary signal in the 250+ kDa, which was expected as MUC5AC is a large 
glycoprotein with many glycosylation sites and a high number of possible 
glycosylation variants (Figure 15D). These signals appeared in all OE19 lanes except 
the reducing diamide treated lane for unknown reasons. HT1080 cell lysates were 
used as a negative control as they are known to have little to no expression of mucins. 
3.6 Validation of AGR2 interactors by immunoprecipitation and 
western blotting 
In order to validate the results seen in the mass spectrometry data, AGR2 
immunoprecipitated lysates were tested by immunoblotting with antibodies specific 
to the new potential interacting proteins. AGR2 Immunoprecipitated OE19 lysates 
were prepared as described previously with and without diamide treatment and with 
NEM trapping. Samples were run under reducing western blotting conditions and 
immunoblotted back for the protein of interest. 
MUC5AC was successfully detected in AGR2 immunoprecipitated OE19 lysates 
analysed by western blotting (Figure 16A). Similar to results seen in Figure 15D, the 
MUC5AC signal again appeared as a smear in all lanes it was observed in. These 
included both the untreated and diamide treated lanes of the IP, appearing stronger 
in the diamide treated IP lane. Faint bands in the 50 kDa region of the IP lanes are 
assumed to be IgG heavy chain cross-reactivity. These results show clearly that 
MUC5AC is being retained after AGR2 immunoprecipitation of OE19 lysates. An AGR2 
immunoprecipitation probed with a BiP pAb successfully detected a signal in the 78 
kDa region in the diamide treated AGR2 IP lane (Figure 16B). This signal was very 
weak compared to the input and supernatant lanes, however it is clearly visible when 
compared to the untreated and IgG only IP lanes. 
Like previous proteins, detection of ERp29 was first attempted after AGR2 
immunoprecipitation using an ERp29 pAb (ab11420) in western blotting (Figure 17A). 
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Figure 15: Verification of expression of ERp29, GAL4, ZG16B and MUC5AC in OE19 
cells. 
The expression of AGR2 interacting proteins detected from mass spectrometry was tested 
with reducing western blotting of OE19 lysates. (A) ERp29 pAb (ab11420) tested against 
OE19 lysates treated with and without diamide and with NEM. Bands in the 29 kDa region 
represent the ERp29 monomer. (B) GAL4 mAb (EPR12710(B)) tested against OE19 lysates 
treated with and without diamide and with NEM. Strong bands in the 36 kDa region 
represent the GAL4 protein. (C) ZG16B mAb (817310) tested against OE19 lysates treated 
with and without diamide and with NEM. No band appeared in the expected 22 kDa range 
and other bands are assumed to be unintentional cross-reactivity. (D) MUC5AC mAb 
(ab198294) tested against OE19 lysates, treated with and without diamide and with NEM. 
Non-distinct signals appeared at high molecular weights in almost all OE19 lanes. HT1080 
lysates used as negative controls. 
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However, this attempt was unsuccessful and no ERp29 signal could be seen in the 
AGR2 IP lanes, partially due to excessive background on the blot. This experiment 
was attempted multiple times, with persistent background issues, without 
successfully detecting an ERp29 band in an AGR2 IP lane (data not shown). As the 
ERp29 pAb described as suitable for IP by the supplier, it was decided to 
immunoprecipitate with the ERp29 pAb and analyse through western blotting with 
the AGR2 mAb (D9V2F). The immunoprecipitation conditions used previously were 
applied to the ERp29 IP and the results of this experiment can be seen in Figure 17B. 
Signals were detected in the AGR2 monomer range, however, they were present in 
all IP lanes including the immunoprecipitate without lysate added, therefore it was 
concluded that the signal present was due to cross-reactivity with the IgG light chain 
and the interaction between ERp29 and AGR2 could not be independently verified. 
After AGR2 immunoprecipitation, GAL4 could not be detected by western blotting 
(Figure 18A). Strong monomer bands could be seen in both the input and supernatant 
lanes but was entirely absent in the AGR2 IP lanes. Considering this data and the low 
peptide count observed in the MS data it was concluded that there was any 
interaction between AGR2 and GAL4 was weak, and further experiments on the 
putative interaction between GAL4 and AGR2 were discontinued. When probing an 
AGR2 IP with an ERp57 pAb it was observed that the ERp57 signal appeared at almost 
exactly the same height on the acrylamide gel as the IgG heavy chain (Figure 18B). 
This resulted in a similar issue to that observed in the ERp29 IP probed back for AGR2; 
the IgG cross-reactivity obscured any ERp57 signal and rendered the results 
inconclusive. 
Probing an AGR2 IP with a PrdxIV mAb 7A1 revealed a signal in the diamide positive 
lane providing further evidence that an interaction occurred between AGR2 and 
PrdxIV (Figure 19A). The reason for the lack of heavy chain cross-reactivity on this 
blot is that the PrdxIV mAb was raised in mice and does not readily react with the 
AGR2 IP mAb ab76473 raised in rabbits. ERp44 was also successfully detected after 
AGR2 immunoprecipitation, as represented by a band in the expected 44 kDa region 
(Figure 19B). Again, this was most prominent in the diamide treated IP lane, although 
it could be argued that a very faint signal was present in the corresponding location 
of the untreated IP lane. Finally, probing an AGR2 IP for calnexin (CNX) produced a 
distinct band in the 90 kDa range where CNX migrates on an acrylamide gel (Figure 
20). This was also only visible in the diamide treated AGR2 IP lane, however CNX was 
detected in both untreated and diamide treated MS samples indicating that this 
interaction may be strengthened by diamide but still occurs in its absence. Successful 
detection of PrdxIV, ERp44 and calnexin by western blotting analysis of AGR2 
immunoprecipitated lysates supports the claim that these proteins are all involved in 
the interactions of AGR2. 
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Figure 16: Validation of AGR2 interactions with MUC5AC and BiP. 
OE19 lysates treated with and without diamide and with NEM were immunoprecipitated 
with the AGR2 mAb ab76473 and immunoblotted back for the protein of interest. (A) 
AGR2 immunoprecipitation probed with the MUC5AC mAb EPR16904. Strong signals in 
the IP:AGR2 lanes showed that MUC5AC was retained after AGR2 immunoprecipitation. 
(B) AGR2 immunoprecipitation probed back with BiP pAb 3183. A faint signal in the 
diamide treated AGR2 IP lane showed BiP was retained after AGR2 immunoprecipitation. 
A 
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Figure 17: Validation of AGR2-ERp29 interactions. 
OE19 lysates treated with and without diamide and with NEM were immunoprecipitated 
with the AGR2 mAb ab76473 and immunoblotted back for the protein of interest. (A) 
AGR2 immunoprecipitation probed back with the ERp29 pAb ab11420. High background 
and an overall weak ERp29 signal resulted in no interaction being observed. (B) ERp29 
immunoprecipitation probed back with the AGR2 mAb D9V2F. Results inconclusive as 
bands appeared in all IP:ERp29 lanes including the IgG only and were therefore assumed 
to be the IgG light chain. 
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Figure 18: Validation of AGR2 interactions with GAL4 and ERp57. 
OE19 lysates treated with and without diamide and with NEM were immunoprecipitated 
with the AGR2 mAb ab76473 and immunoblotted back for the protein of interest. (A) 
AGR2 immunoprecipitation probed back with the GAL4 mAb EPR12710(B). No signal was 
detected in the expected 36 kDa region of either AGR2 IP lane indicating that GAL4 was 
not retained after AGR2 immunoprecipitation. (B) AGR2 immunoprecipitation probed 
back with an ERp57 pAb G117. The IgG heavy chain obscured the signal in the expected 
57 kDa region rendering the results inconclusive. 
A 
B 
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Figure 19: Validation of AGR2 interactions with PrdxIV and ERp44. 
OE19 lysates treated with and without diamide and with NEM were immunoprecipitated 
with the AGR2 mAb ab76473 and immunoblotted back for the protein of interest. (A) 
AGR2 immunoprecipitation probed back with the PrdxIV mAb 7A1. The clear band 
appearing in the diamide treated AGR2 immunoprecipitated lane shows PrdxIV was 
retained after AGR2 immunoprecipitation. (B) AGR2 immunoprecipitation probed back 
with an ERp44 mAb D17A6. The band appearing in the expected 44 kDa region of the 
diamide treated AGR2 IP lane shows ERp44 was retained after AGR2 
immunoprecipitation. 
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Figure 20: Validation of an AGR2-CNX interaction. 
OE19 lysates treated with and without diamide and with NEM were immunoprecipitated 
with the AGR2 mAb ab76473 and immunoblotted back for CNX. AGR2 
immunoprecipitation probed back with a CNX mAb. A single clear band was present in the 
diamide treated AGR2 immunoprecipitated lane indicating that CNX was retained after 
AGR2 immunoprecipitation. 
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3.7 Transfection of OE19 cells with a Myc-tagged ERp29 cDNA 
construct 
Peptides corresponding to the ERp29 protein were detected in two of the four 
samples analysed by MS (Tables 1-4), providing convincing evidence that an 
interaction was taking place between AGR2 and ERp29. Attempts to validate this 
observation through western blotting of AGR2 and ERp29 immunoprecipitated 
lysates (Figure 17A & B) were unsuccessful. Therefore, a transfection experiment was 
initiated attempting to transiently express Myc-tagged ERp29 in OE19 cells. Once 
OE19 cells are expressing Myc-tagged ERp29 it will then be possible to use an anti-
Myc antibody in place of the ERp29 antibody. Blotting an AGR2 immunoprecipitation 
with an anti-Myc antibody should remove the issues with excessive background 
signal previously encountered. Alternatively, immunoprecipitating with an anti-Myc 
antibody and probing back with an AGR2 antibody may reduce the issues with IgG 
light chain cross-reactivity as a different antibody will be used. 
As the transfection protocol had not yet been fully optimised for Myc-tagged ERp29 
cDNA, transfection of OE19 cells was tested with two different concentrations of 
cDNA. A mock transfection was also performed as well as an Ero1α transfection 
which had previously been optimised and therefore served as a positive control. 
After transfection, cells were lysed and run on a western blot probed with an anti-
Myc mAb (Figure 21). Unfortunately, no signal was detected in either ERp29 
transfected lane, showing that the OE19 cells did not express Myc-tagged ERp29. A 
band was detected in the Ero1α lane indicating that the transfection protocol was 
carried out successfully. A faint band also appeared in the mock treated lane, possibly 
due to some non-specific cross-reactivity. Transfection with Myc-tagged ERp29 cDNA 
was unsuccessful and it was decided to focus on other potential interacting partners. 
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Figure 21: Transfection of OE19 cells with Myc-tagged ERp29 cDNA. 
OE19 cells were transfected with a Myc-tagged ERp29 cDNA construct using the 
Lipofectamine 3000 Reagent. Ero1α cDNA served as a positive control. Western blotting 
with an anti-Myc mAb show a band in the Ero1α lane which was entirely absent in both 
ERp29 lanes, showing that the transfection was unsuccessful.  
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3.8 Co-localisation of AGR2 and PrdxIV in OE19 cells 
PrdxIV was successfully detected in mass spectrometry analysis of AGR2 
immunoprecipitated OE19 lysates and subsequently detected through western 
blotting analysis of AGR2 immunoprecipitated OE19 lysates. To provide further 
evidence that an interaction takes place between these two proteins a co-
immunofluorescence experiments were set up. Utilising two different fluorophore-
conjugated secondary antibodies it was possible to observe two different proteins 
simultaneously and from this determine their degree of co-localisation. 
Cells were grown on coverslips, fixed in PFA, permeabilised in Triton X-100 and 
stained with either the AGR2 D9V2F rabbit mAb, the PrdxIV 7A1 mouse mAb or both. 
Fluorophore-conjugated secondary antibodies donkey anti-rabbit Alexa Fluor 594 
(red) and donkey anti-mouse Alexa Fluor 488 (green) were applied to all coverslips, 
along with DAPI. Images were taken on the Zeiss LSM 880 Confocal Microscope. Both 
AGR2 (red) and PrdxIV (green) showed a similar perinuclear staining to the AGR2/PDI 
immunofluorescence presented in Figures 1-5. These results indicate that AGR2 and 
PrdxIV are both localised to the ER of OE19 cells. When merging both AGR2 and 
PrdxIV channels (Figure 22D), a very strong correlation between the AGR2 signal and 
the PrdxIV signal (yellow) was observed. This high degree of overlap between these 
two proteins supports the claim that AGR2 and PrdxIV are appropriately localised to 
interact with each other. 
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Figure 22: AGR2 and PrdxIV co-localise in OE19 cells. 
Immunofluorescence was performed on OE19 cells with either the D9V2F AGR2 mAb, the 
7A1 PrdxIV mAb or both. All slides were stained with both anti-rabbit ALEXAFluor 594 and 
anti-mouse Alexa Fluor 488. (A) Secondary antibody only. (B) 7A1 PrdxIV mAb. (C) D9V2F 
AGR2 mAb. (D) both 7A1 PrdxIV mAb and D9V2F AGR2 mAb. Strong co-localisation was 
observed when combining both AGR2 and PrdxIV (D) supporting the claim that these two 
proteins co-localise in the ER. White scale bars represent 10 µm. 
67 
 
3.9 Mucin visualisation 
Western blotting is typically optimal for proteins between 20-200 kDa and therefore 
high molecular weight proteins such as the mucins can be difficult to visualise 
through standard gel electrophoresis and western blotting. Although a strong signal 
was observed previously when probing an AGR2 immunoprecipitation for MUC5AC 
(Figure 16A), this gave smeary and inconsistent results, so it was decided that other 
methods for visualising mucins should be explored. 
3.9a Deglycosylation of mucins 
During synthesis, secreted mucin proteins travel through the secretory pathway 
where they undergo extensive glycosylation before being ejected from the cell. These 
glycosylation events occur to varying extents on each molecule and result in a mucin 
population with variable molecular weights. When analysing MUC5AC after western 
blotting, this resulted in large non-distinct smears as seen in Figure 16A. The theory 
behind this experiment was that by deglycosylating an OE19 lysate it would be 
possible to remove some of the variation in mucin molecular weight and 
subsequently observe more distinct bands after western blotting analysis, allowing a 
clearer picture of the expression of mucins within a sample. 
The New England Biolabs PNGase F protocol was chosen as the method for 
deglycosylation. Both denaturing reaction conditions and non-denaturing reaction 
conditions were tested. Under denaturing conditions, the sample is heated to 100°C 
for 10 minutes to remove the secondary structure of the folded protein and allow 
full deglycosylation. By comparing denaturing conditions to non-denaturing 
conditions, a comparison can be made to determine the extent of reaction 
completion. OE19 cell lysates without diamide or NEM treatment were subjected to 
protein determination using the Bradford assay and deglycosylated as per the New 
England Biolab protocol. Samples were then analysed by reducing and non-reducing 
western blotting (Figure 23). 
After probing with a MUC5AC mAb distinct bands appeared in both the untreated 
OE19 lysate and the OE19 lysate treated under non-denaturing reaction conditions, 
under non-reducing western blotting conditions. Distinct bands were observed in the 
denaturing deglycosylated sample, indicating that the glycosylation was successful. 
However, these bands were also observed in the untreated sample and therefore 
these distinct bands were unlikely to be a product of the deglycosylation steps taken. 
Non-distinct smears could also still be seen at the top of the blot. The absence of any 
signal including background noise on the non-reducing denaturing sample and the 
lysate and non-denaturing samples run under reducing conditions was likely due to 
a transferring issue. Under reducing conditions, the majority of the denaturing 
sample lane could still be seen and the absence of any signal shows that the 
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deglycosylation was not successful. Overall, experiments to improve the detection of 
MUC5AC by deglycosylation were not successful. 
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Figure 23: MUC5AC deglycosylation using PNGase F.  
OE19 lysates were subjected to either denaturing or non-denaturing 
deglycosylation with PNGase F. Deglycosylated samples were run on 8% 
acrylamide gels and analysed by western blotting with a MUC5AC mAb. Distinct 
bands appeared in the lysate and non-denaturing non-reducing lanes but were 
absent from all other lanes. L = untreated lysate, ND = non-denaturing 
deglycosylated lysate, D = denaturing deglycosylated lysate. 
70 
 
3.9b Alcian Blue staining of mucins 
Alcian Blue is a polyvalent basic dye used to stain acidic polysaccharides and has 
widely been used as a stain for mucins (Steedman, 1950). Use of the Alcian Blue stain 
in SDS-PAGE applications has previously been demonstrated as a method for 
visualising mucins separated on a gel (Cowman et al., 1984).  It was therefore decided 
to test this visualisation method on OE19 and OE33 lysates. 
OE19 and OE33 lysates were separated by 8% acrylamide SDS-PAGE, as described 
previously, followed by staining in 0.5% Alcian Blue plus 2% aqueous acetic acid for 
45 minutes. Gels were then destained in 2% aqueous acetic acid for 15 minutes and 
an image of the gel was taken with a standard office scanner (Figure 24). It could be 
argued that the Alcian Blue stain was localised more towards the top of the gel in 
lanes OE19 and OE33 lysates were loaded – the location mucins have previously been 
observed. However, nothing more than diffuse non-specific staining was achieved in 
this and subsequent experiments. 
Although through mass spectrometry analysis glycoproteins were detected in the 
OE19 cell line, if the experiment was to be repeated again it would benefit from the 
inclusion of a cell line with a high mucin content, or even a purified glycan, to serve 
as a positive control. 
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Figure 24: OE19 and OE33 lysates separated by SDS-PAGE and stained with 
Alcian Blue. 
Duplicate OE19 and OE33 lysates were run on an 8% acrylamide gel and then stained for 
acidic polysaccharides with 0.5% Alcian Blue in 2% aqueous acetic acid. Alcian Blue stain 
did not stain specific proteins in the gel. Staining at the top of the gel could be due to the 
presence of mucins, however it is very non-specific.  
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3.9c Partial trypsinisation of mucins 
Another method used to attempt to visualise MUC5AC was limited proteolysis 
through limited trypsin digestion. Trypsin is a serine protease which can be applied 
to cell lysates to digest the proteins into smaller peptide fragments (Dias-Gunasekara 
et al., 2006; Magnuson et al., 2005). As traditional western blotting is optimized for 
proteins in the 20-200 kDa range, this method can be applied to large proteins such 
as mucins, fragmenting them into peptides more easily detectable by western 
blotting analysis. 
To test partial trypsinisation on OE19 lysates, trypsin concentrations of 0, 0.25, 1.25 
and 2.5 µg/mL were used. After a 30-minute incubation digestion was terminated 
through the addition of soybean trypsin inhibitor (SBTI). Lysates were run on an 8% 
acrylamide gel and analysed by reducing western blotting. Probing the membrane 
with a MUC5AC mAb resulted in no signal being detected (data not shown). The 
membrane was then re-probed with a PDI pAb to test for trypsinisation (Figure 25). 
It is expected that trypsin would reduce the size of the 60 kDa band of PDI and 
produce new bands at lower molecular weights in the 35-45 kDa range (Wang et al., 
2010). When probing with a PDI pAb no additional bands were observed at lower 
molecular weights. The only difference observed was in the 2.5 µg/mL lane where 
the band was reduced in size, however this band remained defined in the 60 kDa 
region. As an 8% acrylamide gel was used, it is possible that some PDI fragments may 
have migrated off the bottom of the gel and are therefore not visible. From these 
experiments we were not able to determine whether or not trypsinisation was 
successful, but due to time pressures we were forced to move on. 
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Figure 25: Limited proteolysis of OE19 lysates through partial trypsinisation. 
OE19 lysates were subjected to limited proteolysis through the addition of varying 
concentrations of trypsin to digest samples. Lysates were separated by SDS-PAGE and 
western blotting and initially probed with a MUC5AC mAb. When no signal appeared, the 
membrane was re-probed with a PDI pAb. PDI bands did not show the expected 
fragmentation expected after trypsinisation. 
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3.10 In vivo AGR2-PrdxIV interaction testing using mouse stomach 
tissue 
The OE19 cell line has provided a convenient cell culture model to test the 
interactions AGR2 makes with other proteins and has revealed multiple AGR2 
interactions for follow up. However, an immortalised cell line does not replicate the 
complex environment of a tissue. Therefore, to provide further evidence to support 
the claim that AGR2 interacts with PrdxIV, and to test this claim in an in vivo system, 
a mouse model was chosen. Mouse stomach tissue was chosen to test this 
interaction as AGR2 and PrdxIV are both known to be expressed in stomach tissue. 
Male mice aged 8-12 weeks were sacrificed in accordance with the Animals (Scientific 
Procedures) Act (1986) by trained personnel in the Life Sciences Support Unit at 
Durham University. After removal from the body of the mouse, the stomach was cut 
into 4 similarly sized pieces and thoroughly cleaned in PBS. These stomach sections 
were treated with or without diamide and with or without NEM creating four 
separate treatment conditions. After treatment cells were scraped into PBS, pelleted 
and transferring to lysis buffer (with or without NEM). Lysates were analysed by 
western blotting with an AGR2 mAb and then subsequently re-probed with a β-actin 
mAb (Figure 25). OE19 lysates were run as a positive control for AGR2. 
Clear AGR2 bands were detected in two of the four mouse stomach lysates 
(+diamide, +NEM and -diamide, -NEM) and a faint band appeared in one of the other 
lanes (+diamide, -NEM), although this may have been due to sample over-spill. 
Reprobing for β-actin revealed there was limited protein in the two lanes lacking 
AGR2 signal (-diamide, +NEM and +diamide, -NEM). Lower molecular weight bands 
in the OE19 lanes of the β-actin reprobe were assumed to be persisting AGR2 signal. 
A positive AGR2 signal in two of the lanes demonstrated that lysates contained AGR2 
and therefore it was decided to immunoprecipitate these lysates with an AGR2 mAb 
and attempt to detect PrdxIV within that AGR2 immunoprecipitate. 
Immunoprecipitation was carried out as previously described for OE19 lysates using 
the EPR3278 AGR2 mAb and a western blot probed with a PrdxIV mAb was used to 
detect a PrdxIV signal. When probing back with a PrdxIV mAb, background signal on 
the blot obscured any evidence of a signal in the immunoprecipitated lanes (data not 
shown). The lack of trapped complexes in the non-reducing stomach samples 
suggested that the procedure for isolating AGR2 complexes from tissues requires 
further optimisation. Taken together with the limited protein recovery that was 
achieved after tissue lysis, it was decided to focus on expression studies of AGR2 in 
cancer tissues. 
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Figure 26: AGR2 expression in lysates recovered from mouse stomach tissue. 
Stomach tissue was treated with and without diamide and NEM and lysed. Lysates were 
run under reducing and non-reducing conditions and probed for both AGR2 (A) and β-
actin (B). OE19 lysates were run alongside mouse lysates as a positive control. Bands 
appearing in the +/+ and -/- lanes (A) show AGR2 is present in the mouse stomach. 
Reprobing for β-actin showed limited protein in -/+ and +/- lanes as well as AGR2 signal 
persisting (B). 
A 
B 
76 
 
3.11 Immunohistochemical analysis of oesophageal tissue sections 
As explained previously the transition from normal oesophageal tissue to Barrett’s 
oesophagus and eventually oesophageal adenocarcinoma is accompanied by 
changes in tissue morphology and mucin expression. Previous histological studies of 
Barrett’s oesophagus and normal oesophageal tissue provided the basis for 
differentiating between the two tissue types (Hao et al., 2006). Normal oesophageal 
tissue is characterised as a simple squamous epithelium, homogeneous in nature and 
lacking glandular structures, whereas metaplasia induced in Barrett’s oesophagus 
results in histology resembling that of the stomach, with glandular structures 
present. We sought to demonstrate this transition through staining of various 
paraffinized tissue sections, including both immunohistochemical staining for AGR2 
as well as Alcian Blue staining of mucins. The following four different tissue sections 
were chosen: normal oesophagus, Barrett’s oesophagus, oesophageal junction 
tumour and oesophageal tumour. These provide a range of cancer progression to 
test for both AGR2 and mucin expression. 
Paraffinized sections on slides were provided by YKS Viswanath and Julie Walker, 
James Cook University Hospital, Middlesbrough. Slides were deparaffinized with 
xylene and ethanol, hydrated and either stained for AGR2 using the D9V2F AGR2 mAb 
through the DAB immunohistochemical staining method or stained for mucins with 
Alcian Blue.  
AGR2 expression can be clearly seen in Barrett’s tissue, OG junction tumour and 
oesophageal tumour tissue, visible as a brown stain (Figures 27 & 28). This staining is 
entirely absent from the normal oesophagus demonstrating the strong induction of 
AGR2 derepression in malignant and pre-malignant oesophageal tissue.  
Similar to the distribution of AGR2 staining, mucin staining, visible as a blue 
colouration, was present in all tissue sections except the normal oesophagus (Figure 
29 & 30). Alcian Blue staining was highly localised to clusters of secretory granules of 
varying size and shape, with little to no specific staining in the surrounding tissue. 
When comparing these Alcian Blue stained clusters to the same clusters on slides 
stained for AGR2 it is clear that they also contain AGR2 expression.  
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Figure 27: Immunohistochemical staining of AGR2 in normal oesophagus and Barrett’s oesophagus tissue sections. 
Human tissue sections from normal oesophagus (OE) and Barrett’s oesophagus (BO) were immunohistochemically stained for AGR2 using the D9V2F AGR2 
mAb (brown). Tissue was also stained with haematoxylin for cell nuclei. Controls were performed without the D9V2F AGR2 mAb. Barrett’s oesophagus 
tissue sections show strong brown AGR2 staining (black arrow) representing strong AGR2 expression, which is entirely absent in normal oesophagus. Black 
squares on x4 magnification show areas magnified to x10. Scale bars represent 1 mm. 
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Figure 28: Immunohistochemical staining of AGR2 in oesophageal junction tumour and oesophageal tumour tissue sections. 
Human tissue sections from oesophageal junction tumour (OJ) and oesophageal tumour (OT) were immunohistochemically stained for AGR2 using the 
D9V2F AGR2 mAb (brown). Tissue was also stained with haematoxylin for cell nuclei. Controls were performed without the D9V2F AGR2 mAb. Both tissue 
types show strong brown AGR2 staining (black arrows) representing strong AGR2 expression. Black squares on x4 magnification show areas magnified to 
x10. Scale bars represent 1 mm. 
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Figure 29: Alcian Blue staining of mucins in normal oesophagus and Barrett’s oesophagus tissue sections. 
Human tissue sections from normal oesophagus (OE) and Barrett’s oesophagus (BO) were stained for mucin with Alcian Blue. Tissue was also stained with 
haematoxylin for cell nuclei. Highly localised Alcian Blue staining can be seen in glandular clusters in BO but is entirely absent in OE sections. Control 
sections displayed are Alcian Blue negative, but DAB stained for AGR2 as in Figures 27 & 28. Glandular structures in BO display both Alcian Blue staining 
as well as DAB-AGR2 staining showing similarities in expression localisation. Scale bars represent 1 mm. 
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Figure 30: Alcian Blue staining of mucins in oesophageal tumour tissue sections. 
Human tissue sections from oesophageal tumour (OT) were stained for mucin with Alcian Blue. Tissue was also stained with haematoxylin for cell nuclei. 
Similarly to Barrett’s oesophagus in Figure 29, Alcian Blue staining can be seen in glandular clusters in oesophageal tumour tissues sections. Control 
oesophageal tumour sections displayed are Alcian Blue negative, but DAB stained for AGR2 as in Figures 27 & 28. Again, similar to BO in figure 29, glandular 
structures in OT display both Alcian Blue staining and DAB-AGR2 staining (brown) showing similarities in expression localisation. Scale bars represent 1 
mm. 
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3.12 ER chaperone expression in OE19 vs OE33 cells 
The OE19 oesophageal adenocarcinoma cell line was identified as pathological stage 
III (UICC) and showed moderate differentiation while the OE33 oesophageal 
adenocarcinoma cell line was identified as pathological stage IIA (UICC) and showed 
poor differentiation. This difference in cancer progression between these two cell 
lines allows the opportunity to study their differences and from that infer changes 
that may be brought about by cancer progression in human tissue.  
Expression levels of a variety of ER chaperones were tested in both OE19 and OE33 
cell lines by SDS-PAGE and western blotting (Figure 31). These included AGR2, PrdxIV, 
ERp29, PDI and calnexin, with β-actin used as a loading control. Quantification of 
western blotting signals was performed with ImageJ with densities being calculated 
relative to the cell line’s β-actin density. These relative densities (OE19/OE33) can be 
seen in Table 5. AGR2 expression was significantly higher in OE19 cells. Looking at the 
western blotting results it may be possible there was over-spill from the OE19 lane 
into the OE33 lane, causing an increase in the OE33 signal. It also appears that the 
AGR2 band in OE19 was oversaturated and will therefore likely give an 
underestimation of AGR2 expression. Even considering this it is clear OE19 cells 
express AGR2 much stronger than OE33 cells. 
PrdxIV levels were almost two-fold higher in OE19 cells and ERp29 saw an almost 
50% increase when compared to OE33 cells. As a further progressed cancer cell line, 
OE19 may be overexpressing ER chaperones to keep up with the extra demand from 
a highly proliferating cell, which may be why we see increased levels of PrdxIV and 
ERp29. PDI levels were slightly but not significantly lower in OE19 and calnexin levels 
in OE19 were less than two thirds that of OE33 cells. As stated earlier it would be 
expected that the OE19 further progressed cancer cell line would have higher 
expression of ER chaperones when compared to the less progressed OE33 cancer cell 
line. From this data this appears not to be the case with PDI and calnexin. Calnexin 
does appear to have much lower expression in OE19 cells, however this may be due 
to the unusual shape of the band detected. 
Overall it appears that chaperone expression is either increased in OE19 cells when 
compared to OE33 cells or the expression levels are relatively similar. This data serves 
to illustrate differences between these two cell lines, however, this was only one 
experiment, and only after repeating it multiple times would any significant 
conclusions about relative protein expression levels be deducible between these two 
cell lines. 
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Figure 31: Expression of ER chaperones in OE19 vs OE33 cells. 
Cell lysates made from OE19 and OE33 cells were analysed by SDS-PAGE and western 
blotting for the ER chaperones AGR2, PrdxIV, ERp29, PDI and calnexin. β-actin was used 
as a loading control. 
Table 5: Calculated relative densities of ER chaperone expression OE19 vs OE33 cells. 
Western blotting results show in Figure 31 were analysed and quantified using ImageJ 
and relative densities between OE19 and OE33 cells were calculated. ER chaperones 
expression was similar between the two cell lines with only AGR2 showing much greater 
expression in OE19 cells. 
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4 Discussion 
4.1 The intracellular localisation of AGR2 
The presence of a signal sequence in the primary sequence of AGR2 (Figure 2 from 
introduction) dictates that it is translated into the ER lumen; the question of what 
happens to it after that is still up for debate. A sophisticated system of protein 
retrieval from the cis-Golgi compartment maintains levels of specific ER-resident 
proteins such as the chaperones within the ER. This is mediated by the C-terminal 
target peptide sequence KDEL, which is recognised by KDEL receptors in the cis-Golgi, 
after which retrograde transport is initiated and proteins are transported back to the 
ER lumen (Lewis and Pelham, 1990). AGR2 contains a non-optimal KTEL ER 
localisation signal which may allow localisation outside of the ER. 
Immunofluorescence experiments performed in this study focused on OE19 
oesophageal adenocarcinoma cells stained for both PDI and AGR2. PDI is a known 
ER-resident protein and therefore allowed visualisation of the ER in these cells. AGR2 
staining within these cells showed a similar perinuclear profile of localisation to PDI 
supporting the claim that AGR2 is retained within the ER (Figures 5-8). A similar 
profile of immunofluorescence AGR2 expression was noted by (Dong et al., 2011) 
although they did not use an ER marker for comparison. Another experiment 
performed for this thesis involved co-staining of OE19 cells for both AGR2 and PrdxIV. 
Both proteins showed an almost identical pattern of localisation, which was again 
perinuclear. As PrdxIV is known to be an ER-resident protein (Tavender et al., 2008), 
this supports the claim that AGR2 is localised to the ER in OE19 cells. The ER 
localisation of AGR2 has been shown in other studies (Gupta et al., 2012; Higa et al., 
2011; Park et al., 2009; Zhao et al., 2010) and therefore this observation is consistent 
with the literature. The question of whether AGR2 also leaves the ER to perform 
some of its functions remains possible. To answer this question higher resolution 
microscopy would be required.  
4.2 AGR2 forms disulphide dependent complexes 
AGR2 is a small member of the PDI family of proteins containing only one 
thioredoxin-like domain and one “active site” CXXS motif. Lacking the second 
cysteine residue, this motif does not allow for catalysed oxidase activity, as seen in 
PDI (Nørgaard and Winther, 2001). The presence of only one cysteine residue 
prompts the question of how this cysteine is involved in the interactions AGR2 makes 
with clients, co-chaperones and other interacting proteins. Through this cysteine 
residue, AGR2 can form disulphide bonds with itself, creating homodimers (Patel et 
al., 2013), as well as with client proteins, including MUC2 (Clarke et al., 2016).  
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The oxidant diamide was chosen to induce a change in the redox potential of the cells 
and promote disulphide bond formation. Diamide was initially discovered as an 
oxidiser of the intracellular pool of reduced glutathione (GSH), converting it to the 
glutathione disulphide (GSSG) (Kosower et al., 1969). As GSH reduces disulphide 
bonds, depletion of GSH promotes disulphide bond formation. Depletion of this GSH 
pool has been shown to result in cross-linking of certain proteins, such as PDI to IgM 
in lymphocytes (Roth and Pierce, 1987). Another early study showed that diamide 
may not be entirely specific to GSH and could also oxidise protein-SH groups resulting 
in non-specific modifications (Harris and Biaglow, 1972). These are all points to 
consider when using diamide to monitor protein-protein interactions as it moves 
cells away from physiological conditions. Other effects of diamide have also been 
noted, including depressed DNA synthesis and respiration (Harris and Biaglow, 1972). 
However, changes in protein expression due to these effects will not be noticeable 
for the short treatment time scales used in this thesis. 
Through the use of diamide, in combination with the chemical NEM to alkylate free 
thiol groups and prevent disulphide bond reshuffling, it was possible to trap AGR2 
complexes, visible through non-reducing western blotting (Figure 9). Induction of 
AGR2 complexes was rapid, occurring after only 5 minutes of treatment with 
diamide. Multiple bands were visible in the diamide treated non-reducing lanes in 
addition to smearing at the higher molecular weights representing a variety of AGR2 
complexes. A distinct band appeared at ~34 kDa in the diamide treated non-reducing 
lanes which, due to its molecular weight, was assumed to be AGR2 in its homodimeric 
form, which is in line with the literature (Ryu et al., 2013). Determining the nature of 
the other complexes observed would require more advanced experimental 
techniques and was addressed by the mass spectrometry experiments described in 
section 3.4. A diamide recovery experiment was also performed to investigate the 
stability of these AGR2 complexes (Figure 9B). In the recovery experiments the 
majority of the induced AGR2 complexes persisted for 20 minutes with only one band 
clearly disappearing after recovery. Other studies have shown recovery of diamide 
induced loss of protein-SH groups occurs after just 15 minutes (Harris and Biaglow, 
1972), in contrast to the results in this study. This may be due to differences in 
diamide concentrations used, the alkylation strategy, the cell type, or the cell-specific 
client range of AGR2 compared to other proteins. 
Side by side comparison of reducing and non-reducing conditions clearly showed that 
the AGR2 complexes in OE19 cells are redox (disulphide) dependent as they are 
entirely absent under reducing conditions. As these AGR2 complexes are only visible 
under non-reducing condition they are very likely to occur through the single cysteine 
residue on AGR2. 
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4.3 The effect of ER stress on AGR2 complex formation 
Previous experiments by Simpson and Benham (unpublished data) showed DTT 
modulated AGR2 complex formation. As DTT induces ER stress, one possibility was 
that these complexes may be induced by ER stress. 
To test whether redox independent, ER stress-induced changes in AGR2 dependent 
complex formation could be detected, OE19 cells were treated with thapsigargin as 
well as a bile acid cocktail in low pH media. From western blotting results, 
thapsigargin treated samples did not show any sign of complex formation when 
probing for AGR2 (Figure 10A). Low pH media alone did not have an effect on AGR2 
complexes (Figure 11C). When treating OE19 cells with low pH media supplemented 
with bile acids (Figure 11D), some additional bands were observed, although 
background signal partially obscured the results and bands also appeared in the 
reducing lanes. Overall these experiments indicated that ER stress, bile acids and pH 
did not affect AGR2 complex formation. This would suggest that the AGR2 complexes 
observed through non-reducing western blotting are not dependent on the redox 
state of the ER but not on ER stress. 
It is, however, possible that prolonged ER stress may induce changes in gene 
expression, not visible in these experiments due to the short time scales. The 
chaperone BiP is one such protein that is induced after ER stress. As AGR2 has been 
shown to interact with BiP, it is possible that the AGR2-BiP interaction could be 
induced by elevated levels of the BiP protein resulting from ER stress. However, a 
series of experiments would need to be carried out over longer time scales to verify 
this. 
4.4 AGR2 associates with mucins and other ER chaperones 
Although it is well known that AGR2 plays an important role in a variety of different 
types of cancer and that it is required for correct synthesis and secretion of multiple 
mucin isoforms, the exact mechanism through which AGR2 performs these functions 
remains elusive. Previous interactions studies involving AGR2 have involved the use 
of yeast two-hybrid screens to detect potential novel interacting proteins. Proteins 
discovered through this technique include the DNA-binding protein Reptin (Maslon 
et al., 2010) along with the metastasis-associated GPI-anchored C4.4a protein and 
extracellular alpha-dystroglycan (DAG-1) (Fletcher et al., 2003). Due to the nature of 
these interacting proteins, these interactions are assumed to be involved in AGR2’s 
oncogenic functions. However, the yeast two-hybrid approach does not take account 
of the topological issue imposed by the ER membrane. 
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The mechanisms though which AGR2 carries out its physiological function are less 
well known. Through knockout studies in mice, AGR2 has been shown to be essential 
for MUC2 synthesis and co-immunoprecipitation experiments have shown MUC2 is 
retained after AGR2 immunoprecipitation. Removal of the single cysteine residue in 
AGR2 prevents the interaction between AGR2 and MUC2 (Park et al., 2009). Further 
knockout studies showed that loss of AGR2 also resulted in a greater than 50% 
reduction in the levels of airway mucins MUC5AC and MUC5B (Schroeder et al., 
2012). AGR2 has also been shown to associate with BiP through its dimeric form (Ryu 
et al., 2013). Although AGR2 has widely been described as an important part of the 
mucin synthesis machinery, the mechanism through which AGR2 is involved in mucin 
production are largely unknown. 
Here we have demonstrated a trapping and immunoprecipitation approach for 
detecting AGR2 interacting proteins. The oxidising agent diamide was used to induce 
oxidising conditions and promote disulphide bond formation, and the alkylating 
agent NEM was used to alkylate free thiol groups on proteins and prevent disulphide 
bonds reshuffling. Additionally, cells were lysed using the non-ionic detergent Triton 
X-100, which was chosen as it is considered non-denaturing and generally less 
destructive to protein interactions when compared to harsher detergents. Through 
these conditions we have been able to preserve interactions of AGR2 and isolate 
AGR2 with its interacting partners. 
Mass spectrometry analysis revealed both mucins MUC5AC and MUC5B were co-
immunoprecipitated with AGR2 in all immunoprecipitated samples (Tables 1-4), 
consistent with the literature (Schroeder et al., 2012). Consistently high peptide 
counts for both of these mucin isoforms suggests that they are the primary clients 
for AGR2 in OE19 cells. Proteomic and western blotting analysis also revealed 
multiple ER chaperones were retained after AGR2 IP including: ERp29, ERp44, ERp57, 
PrdxIV, CNX, Ero1α and P5, as well as the previously known interactor BiP. The lectins 
GAL4 and PAUF/ZG16B were also detected in the MS data. Lectins bind to 
carbohydrates like those found on the highly glycosylated mucins and therefore hold 
the potential to be involved in AGR2/mucin interactions. However, low confidence in 
the MS results due to low peptide counts and negative results from immunoblotting 
of AGR2 immunoprecipitates meant that an interaction between AGR2 and GAL4 or 
ZG16B could not be confirmed. 
Of the two mucin isoforms identified in the MS data MUC5AC was chosen for further 
analysis due to it having higher overall peptide counts. The presence of MUC5AC in 
the AGR2 immunoprecipitate was confirmed through western blotting of an AGR2 
immunoprecipitation with a MUC5AC mAb. These results suggest that AGR2, in OE19 
cells, is acting as a chaperone in the quality control of MUC5AC. The presence of 
MUC5AC in OE19 cells also suggests that this cell line has undergone the transition 
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similar to that found in Barrett’s oesophagus, as Barrett’s oesophagus is known to 
express MUC5AC (Arul et al., 2000). It is worth noting that the association between 
AGR2 and MUC5AC could be due to a direct interaction, or an indirect interaction 
with a third protein with which both AGR2 and MUC5AC interact. The high peptide 
counts obtained make the latter explanation unlikely, but this possibility could be 
resolved by performing re-immunoprecipitation studies. AGR2 may be part of a 
mucin folding complex, which has yet to be fully elucidated. 
In both AGR2 immunoprecipitates from diamide treated OE19 cells, ERp29 was 
detected by mass spectrometry (Tables 2 & 4). ERp29 is a small ubiquitous ER-
resident chaperone thought to play an important role in secretion. It is a component 
of the thyroglobulin folding complex; thyroglobulin being the major secretory 
product of the thyroid epithelial cells (Baryshev et al., 2006). ERp29 is not considered 
a protein disulphide isomerase as it does not contain an a domain and hence lacks 
the traditional thioredoxin motif found in PDI family members. Surprisingly, ERp29 
was found to be retained after AGR2 immunoprecipitation only in samples treated 
with diamide, suggesting its presence was due to induced disulphide bonds or a 
change in the redox poise of the ER. It is possible that ERp29 co-associates with 
another protein retained in the IP, and that this protein has a diamide-induced 
interaction with AGR2. 
Verification of MS results revealed several ER chaperones were retained after AGR2 
immunoprecipitation and detectable by western blotting, supporting an interaction 
with AGR2. These included: ERp44, PrdxIV and CNX. 
ERp44 is a chaperone protein preferentially binding client proteins in the acidic 
environment of the cis Golgi (Vavassori et al., 2013). It is known to forms mixed 
disulphide bonds with Ero1α, Ero1β and folding intermediates, including partially 
unfolded Ig subunits (Anelli et al., 2002, 2003). Through experiments with a truncated 
ribophorin mutant (Ri332) lacking cysteine residues, ERp44 has been shown to 
interact through formation of inter-chain disulphide bonds (Anelli et al., 2002). MS 
data from our study show ERp44 was only found in a diamide treated MS sample, 
suggesting that it was retained through interactions involving disulphide bonds, 
which is in line with the literature. ERp44 has also been shown to bind PrdxIV and 
Ero1α, retaining them in the ER as they lack the traditional KDEL ER localisation signal 
(Kakihana et al., 2013). As AGR2 does not contain a KDEL sequence, instead having a 
non-optimal KTEL ER localisation signal, it is possible that ERp44 also assists in 
retaining AGR2 in the ER compartments, which may be why we see it being retained 
after AGR2 immunoprecipitation. 
PrdxIV, was also detected after AGR2 immunoprecipitation (Table 4 & Figure 19). 
PrdxIV is the ER-resident peroxiredoxin enzyme in humans and is capable of 
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metabolising hydrogen peroxide produced by Ero1α, oxidising itself and in turn 
allowing transfer of a disulphide bond to PDI or other PDI family members. PrdxIV 
was detected in our MS data with relatively high confidence – a peptide count of 7 
and an unused value of 10.37, although only in the diamide treated sample of the 
second round. Validation of this result through western blotting of AGR2 
immunoprecipitates resulted in a clear PrdxIV signal detected, but again only in the 
diamide treated sample. This suggests the interaction is redox dependent. 
A concern when using an immortalised cell line to monitor protein-protein 
interactions is that interactions occurring in the immortalised cell line may not occur 
in tissues. To address this concern the PrdxIV and AGR2 interaction was tested in 
mouse stomach tissue as it is known to express both proteins. Unfortunately, testing 
this interaction in vivo was technically unsuccessful as the protein recovery method 
from mouse stomach tissue did not provide enough protein for the purposes of 
immunoprecipitation. This may have been partially due to stomach tissue not 
expressing AGR2 to the same degree as the OE19 adenocarcinoma cell line. Co-
localisation immunofluorescence experiments were performed on OE19 cells to 
determine any overlap in intracellular localisation of these two proteins. When co-
staining for both AGR2 and PrdxIV, an almost identical pattern of localisation 
occurred within OE19 cells, providing support to the claim that an interaction occurs 
between AGR2 and PrdxIV (Figure 22). 
CNX was also successfully detected through western blotting of AGR2 
immunoprecipitates (Figure 20). As a lectin chaperone known to assist in 
glycoprotein folding, it is possible that calnexin may play a role in the interactions 
and folding of mucins alongside AGR2. Previous studies have shown CNX does 
support mucin synthesis. Experiments in human colonic adenocarcinoma cells 
demonstrated CNX and the homologous lectin calreticulin (CRT) co-
immunoprecipitated with MUC2, although no interaction was detected with 
MUC5AC for either of these proteins (McCool et al., 1999). As MUC5B was also 
detected in our MS analysis, it is possible that CNX could be interacting with MUC5B. 
Together, CNX and CRT cooperate in what is known as the CNX/CRT cycle of 
glycoprotein folding along with a range of other co-chaperones. One of these co-
chaperones is ERp57, which was also detected in the MS data although could not be 
verified by western blotting due to technical issues. A direct interaction between 
ERp57/CNX and AGR2, if confirmed by immunoprecipitation, could imply that AGR2 
is involved in the calnexin cycle to assist the folding of MUC5AC. 
In summary, detection of proteins through MS analysis of diamide treated AGR2 
immunoprecipitated OE19 lysates provides an unbiased approach for identifying 
AGR2 interacting proteins. Several new interacting partners for AGR2 have been 
identified, including ERp44, PrdxIV, and CNX, as well as several others that require 
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confirmation, including ERp29, ERp57, Ero1α and P5. A diagram summarizing these 
new AGR2 interacting partners is displayed in Figure 32. Here we have taken the first 
steps towards identifying novel players involved in AGR2 function and mucin quality 
control. 
 
 
 
 
 
Figure 32: Summary of interacting partners for AGR2. 
A diagram summarizing the major known interacting partners for AGR2 including ones 
discovered through this thesis. Straight lines indicate binding interactions (whether direct 
or indirect), arrows indicate upregulation of activity and flat ended lines indicate 
inhibition of activity. ERp29, ERp44, ERp57, PrdxIV, Ero1α, P5 and Calnexin were all 
detected through IP/MS during this investigation, and of those, ERp44, PrdxIV and 
CNX were confirmed through western blotting using antibodies specific to these 
new proteins. 
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4.5 Immunohistochemical and Alcian Blue analysis of oesophageal 
tissue sections 
Oesophageal tissue, when transitioning into Barrett’s oesophagus or oesophageal 
adenocarcinoma, exhibits changes in mucin expression along with derepression of 
AGR2 (Hao et al., 2006). Oesophageal tissue sections including normal oesophagus, 
Barrett’s oesophagus, oesophageal junction tumour and oesophageal tumour were 
chosen to represent various stages of oesophageal tumour development and 
analysed for AGR2 and mucin expression. Staining for AGR2 with the AGR2 mAb 
D9V2F revealed strong AGR2 expression in Barrett’s oesophagus, oesophageal 
junction tumour and oesophageal tumour tissues, but little to no expression in 
normal oesophageal tissue (Figure 27 & 28). These results are consistent with the 
findings from Hao et al., (2006) and morphologies of AGR2 expressing regions of the 
tissue sections show similarities to immunohistochemical images published by Dong 
et al., (2011).  
Staining for mucins with Alcian Blue dye revealed large glandular structures in the 
tissue sections that appeared in all tissue types excluding normal oesophagus 
(Figures 29 & 30). Staining was very specific to these structures and did not occur to 
the same extent elsewhere in the tissue. These structures show similarities to Alcian 
Blue stained oesophageal gland ducts from patients with Barrett’s oesophagus, 
observed in a study by Johnson et al., (2015). However, this study and others show 
Alcian Blue staining of Barrett’s oesophagus with more even distribution than that 
observed in this project (Cabibi et al., 2014; Johnson et al., 2015; Voltaggio et al., 
2011). This may be due to tissue samples that only express mucin in highly localised 
structures. When comparing these structures in Alcian Blue stained tissue with AGR2 
stained tissue it was clear that these cells were also expressing AGR2. This 
overlapping localisation of AGR2 and mucins supports the co-immunoprecipitation 
data and is consistent with the assertion that AGR2 is a chaperone with mucin family 
proteins as its primary clients (Park et al., 2009; Schroeder et al., 2012). 
4.6 ER chaperone expression in OE19 vs OE33 cells 
There is increasing evidence that chaperone proteins play a pivotal role in 
maintaining cellular homeostasis in cancer cells. Gene expression microarray studies 
have shown increased expression of PDI in a variety of cancer types when compared 
to normal tissue (Xu et al., 2014), and cancer stem/progenitor cells from the bone 
marrow of breast cancer patients have shown overexpression of PDI, BiP and Grp94, 
demonstrating activation of the unfolded protein response (UPR) (Bartkowiak et al., 
2010). The UPR has been implicated in hypoxia, a common form of cellular stress 
experienced by growing tumours (Wouters and Koritzinsky, 2008), and both the PERK 
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arm (Bi et al., 2005) and the XBP1 arm (Romero-Ramirez et al., 2004) of the UPR have 
been implicated in cell survival and tumour growth. 
Considering the role ER chaperones have been shown to play in cancer cell 
progression, the expression levels of different ER chaperones were tested in both 
OE19 and OE33 cells. The OE19 cell line was derived from an oesophageal tumour 
classed as pathological stage III (UICC) while the OE33 cell line was derived from a 
tumour classed as pathological stage IIA (UICC). Therefore, by investigating 
expression levels between these two cell lines it was possible to observe differences 
in expression levels between two different stages in tumour progression (Figure 31 
& Table 5). Most notable was the difference in AGR2 expression. OE19 cells strongly 
express AGR2 as shown in the earlier sections of this thesis but was almost entirely 
absent in OE33 cells. This expression profile may have been due to the poor 
differentiation of the OE33 cell line as AGR2 expression has been shown to occur in 
the vast majority of oesophageal adenocarcinomas (DiMaio et al., 2012). Expression 
levels of PrdxIV and ERp29 showed slight increases in expression in the OE19 cell line, 
with calnexin showing decreased expression and PDI showing little difference, when 
compared to the OE33 cell line. Overall a slight increase in ER chaperone expression 
was observed in the further progressed OE19 cancer cell line, which is in line with the 
literature, however, these experiments would need to be repeated before any 
significant changes could be claimed. 
4.7 Future experiments 
Experiments presented in this thesis have made considerable progress towards 
identifying AGR2 interacting proteins, the nature of these interactions and 
identification of the players involved in mucin synthesis in oesophageal 
adenocarcinoma. However, due to its short time scale, there are still many 
unanswered questions.  
Early experiments in this thesis demonstrated AGR2 can form disulphide dependent 
complexes (Figure 9) and subsequently it was shown that AGR2 interacting partners 
could be identified through immunoprecipitation and mass spectrometry analysis 
(Tables 1-4). As the same conditions were used to trap these complexes in both sets 
of experiments, it is assumed that a large portion of the interactions seen were 
disulphide dependent. One possible way of determining whether or not these 
interactions were disulphide dependent would involve removal of the single cysteine 
residue in AGR2. This could be done by inserting a coding sequence representing 
AGR2, with the cysteine residue replaced with a serine, into an expression vector. 
This expression vector would then need to be transfected into OE19 cell with wild-
type AGR2 expression inhibited, likely through shRNA silencing. Immunoprecipitation 
and mass spectrometry experiments, as described in this thesis, carried out with a 
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cell line expressing an AGR2 protein lacking cysteine residues would reveal whether 
these interactions are disulphide dependent. Any proteins retained after 
immunoprecipitation with this cell line would be assumed to associate with AGR2 
independently of direct disulphide bonds with AGR2. 
In experiments in this thesis, mucin visualisation through western blotting proved 
difficult, as demonstrated by the multiple attempts to improve mucin visualisation 
(Figures 23-25). This was due to the large size of the mucin proteins and their variable 
molecular weights caused by varying patterns of glycosylation. Western blotting is 
optimised for proteins between 20-200 kDa and mucins typically migrate well above 
this range. One method not attempted here would be to use gradient gels for SDS-
PAGE separation. Gradient gels are harder to cast that traditional single 
concentration gels but provide much better separation for a wider range of protein 
molecular weights. These gels typically range from 4% to 20%, allowing larger 
proteins such as mucins to travel further into the gel as the initial acrylamide 
percentage is lower. Gradient gels may be an alternative method of visualising 
mucins and might allow for further experiments to be performed investigating 
mucins, such as determining expression levels between OE19 and OE33 cells to 
investigate the correlation between AGR2 expression and mucin expression. 
Although ERp44, PrdxIV and CNX were all detected through western blotting of AGR2 
immunoprecipitated lysates, several other proteins detected through mass 
spectrometry analysis were unable to be detected through western blotting. 
Identification of these proteins was hindered as the primary antibody used in 
western blotting would often react with the light and heavy chains of IgG used in 
immunoprecipitation, thus obscuring the signal of the protein of interest. These 
cross-reactivity issue would likely have been mitigated if the two antibodies used 
were raised in different species. For example, immunoprecipitation was carried out 
with an anti-rabbit AGR2 antibody. If western blotting detection of ERp29 was 
attempted with an anti-mouse ERp29 antibody it is possible the IgG light chain at ~25 
kDa would be absent and the ERp29 band at ~29 kDa would be visible. Alternatively, 
2D gel electrophoresis could have been implemented to further separate proteins 
before detection through immunoblotting. 
Another experiment attempted with limited success was investigation into the in vivo 
interaction between AGR2 and PrdxIV, though the use of a mouse model. These 
experiments were halted as protein recovery from mouse stomach sections was 
limited do to their small size. One way around this would be to move to a larger 
animal such as a rat or rabbit. The larger stomach size of these animals would allow 
more protein to be recovered and hopefully allow an interaction to be observed 
between AGR2 and PrdxIV.  
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4.8 Conclusion 
Experiments in this thesis have shown that AGR2 is strongly expressed in the OE19 
oesophageal adenocarcinoma cell line, and that in this cell line it can form disulphide 
bond dependent complexes, visible through non-reducing western blotting. These 
complexes also appear to not be dependent on ER stress. With this knowledge, a 
novel, unbiased trapping and immunoprecipitation approach was implemented, and 
peptide identification by ESI mass spectrometry has revealed a variety of ER-resident 
proteins that associate with AGR2. The mucins MUC5AC and MUC5B have been 
identified as primary clients of AGR2 in the OE19 cell line, and associations with ER 
chaperones including PrdxIV, BiP, calnexin and ERp44 have been demonstrated and 
verified. Immunohistochemical analysis of oesophageal tissue sections has displayed 
the strong induction of AGR2 expression in the progression to Barrett’s oesophagus 
and oesophageal adenocarcinoma and has revealed co-localisation between AGR2 
and mucin secreting glands. Finally, experiments into ER chaperone expression have 
shown differences in expression between two cell lines representing different stages 
of oesophageal adenocarcinoma. 
Identification of these novel AGR2 interactions has provided the basis for elucidation 
of a mucin quality control system within oesophageal adenocarcinoma and highlights 
potential therapeutic targets for AGR2-positive cancers. 
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